<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-011298
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20060322
<FILING-DATE>20060323
<DATE-OF-FILING-DATE-CHANGE>20060323
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06705102
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v038458_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of March 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number 000-5112</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      March 22, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%">&#160;</td>
            <td colspan="2" width="50%"><font size="2">pSivida Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td width="50%">&#160;</td>
            <td width="1%">&#160;</td>
            <td width="49%">&#160;</td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><em>Chief
              Financial Officer and Company
              Secretary</em></font></td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Open
                Briefing: pSivida Update on Progress</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">&#160;</td>
            <td align="left" valign="top" width="62%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v038458_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Attention
      ASX Company Announcements Platform</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Lodgement
      of Open Briefing</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><IMG SRC="logo.jpg"></div>
            </td>
            <td align="right" valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><IMG SRC="logo2.jpg"></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12,
      BGC Building </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth,
      Western Australia 6000 </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Date
      of lodgement: </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22-Mar-2006</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Title:
      </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Open
      Briefing</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      pSivida. Update on Progress </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Record
      of interview: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited (ASX: PSD) recently announced the publication of long-term trial results
      from a Bausch &amp; Lomb study of Retisert&#8482; as a treatment for chronic
      non-infectious posterior segment uveitis. The three-year study undertaken by
      Bausch &amp; Lomb involved 278 patients at 27 hospitals in the United States and
      one in Singapore. A statistically significant number of eyes treated with
      Retisert&#8482; demonstrated a three-line improvement in vision on an eye chart as
      well as significantly reduced recurrence rates. What impact will this study
      have
      on current sales? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      three-line improvement in vision is a strong result and the study will be used
      to brief doctors treating patients with uveitis. The effectiveness of the drug,
      as demonstrated by this three-year trial data, can only add to the marketability
      of the product in the United States and will be used to seek regulatory approval
      in other regions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      addition, Bausch &amp; Lomb recently appointed global pharmaceutical company,
      Novartis, to co-promote Retisert&#8482; for uveitis in the United States,
      significantly increasing the number of sales representatives dedicated to the
      promotion of Retisert&#8482; in the United States. pSivida receives a significant
      royalty on Retisert&#8482; sales (current wholesale price is US$18,250) which is
      covered by US Medicare. Uveitis is the third largest cause of blindness in
      the
      US with an estimated 175,000 treatable cases and an estimated 800,000
      worldwide.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further
      reporting on the effectiveness of Retisert&#8482; on uveitis will be presented at the
      6</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      International Symposium on Ocular Pharmacology and Therapeutics Conference
      in
      Berlin on 31 March 2006 and the Association for Research in Vision and
      Ophthalmology, Inc. (ARVO) 2006 Annual Meeting on 1 May 2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Concurrent
      to the release of the three-year results of Retisert&#8482; as a treatment for
      uveitis, Bausch &amp; Lomb reported on a controlled clinical trial of Retisert&#8482;
for the treatment of Diabetic Macular Edema (DME). This study involved 197
      patients at hospitals in the United States and results demonstrated a three
      or
      more line improvement on an eye chart at three years, which is defined by the
      FDA as a Gold Standard level of improvement. How does this treatment compare
      to
      the current standard of care? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Diabetic
      Macular Edema is the number one cause of blindness in the United States for
      people under the age of 65 and afflicts about 10 percent of all diabetics with
      an estimated 500,000 treatable cases in the US alone. The results of this study
      have shown that at three years, in addition to improved vision, there was no
      evidence of DME in 58 percent of the eyes receiving the implant versus 30
      percent of eyes receiving the existing standard of care, repeated laser
      surgery.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      study
      also demonstrated at three years, a two-grade improvement in the Diabetic
      Retinopathy Severity score (a measure of the severity of the disease) in 13
      percent of eyes treated with Retisert&#8482; compared to 4 percent of eyes treated
      with the standard of care. Diabetic Retinopathy is a measure of the underlying
      disease rather than diminished vision, which is a symptom of the disease.
      Diabetic Retinopathy occurs when diabetes damages the tiny blood vessels inside
      the retina, the light-sensitive tissue at the back of the eye and usually
      affects both eyes.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Further
      reporting on the effectiveness of Retisert&#8482; on DME will be presented at the
      6</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      International Symposium on Ocular Pharmacology and Therapeutics Conference
      in
      Berlin on 31 March 2006 and the ARVO 2006 Annual Meeting on 4 May 2006.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Will
      you
      seek FDA approval for Retisert&#8482; in DME? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      Bausch
&amp; Lomb own the licensing rights to Retisert&#8482; in all applications, they are
      responsible for any regulatory filing strategy and product commercialisation.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">How
      does
      the outcome of this trial data impact your assessment of Medidur&#8482;, which
      commenced phase III trials for the treatment of DME in October 2005?
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
      these
      Retisert&#8482; and Medidur&#8482; products can deliver the same drug, at a similar rate
      over a similar period of time, it is reasonable to expect the three year results
      from the current phase III Medidur&#8482; trial will be similar to the results from
      the three year data on Retisert&#8482;. In our view, the data therefore reduces
      significantly the approval risk of the Medidur&#8482; product. </font></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">What
      are
      the differences between Retisert&#8482; and Medidur&#8482;? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Both
      products work in the same way, however, Medidur&#8482; is smaller and injectable,
      whereas Retisert&#8482; has a larger drug reservoir and is inserted in a surgical
      procedure. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited acquired Control Delivery Systems (now pSivida Inc.) in December 2005.
      What synergies have been experienced to date and what future synergies do you
      expect to achieve? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      bringing together of our existing platforms and expertise has the potential
      to
      create a leading global bio-nanotech company developing next generation products
      and technologies in the areas of ophthalmology, oncology, and drug delivery
      generally. The acquisition has significant benefits to our shareholders in
      terms
      of future value enhancing prospects. We are particularly excited about the
      potential to integrate BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
      </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      our
      drug delivery technology platform to create next generation treatments for
      a
      broad range of diseases and conditions. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      acquisition has also brought additional product development and regulatory
      expertise to pSivida&#8217;s management team and provided pSivida with an operating
      base in the Boston biotech hub, enhancing our overall visibility as well as
      access to the US scientific and investment communities. Australian publication
      Bioshares recently announced pSivida&#8217;s acquisition of CDS as the &#8216;Biotech
      M&amp;A Deal of the Year&#8217;, citing pSivida&#8217;s increased presence in the US,
      current revenue stream and synergies for combining the two companies&#8217;
technologies and expertise. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Given
      the
      recent progress made in ophthalmology, what new developments are there with
      BioSilicon&#8482;?</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      ophthalmic area has had significant news of late that is reflected in our
      announcements and the maturity of these products. Since the planned acquisition
      of CDS was first announced, there have been a number of significant value-adding
      announcements including; several new evaluation agreements with large pharmas
      in
      ophthalmology; Retisert&#8482; was granted full Medicare cover in the US; Novartis
      began co-promoting Retisert&#8482; in the US with Bausch &amp; Lomb; and Bausch &amp;
Lomb released important three year trial data on Retisert&#8482; for uveitis and
      DME.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      relation to BioSilicon&#8482;, there has been strong progress made in this important
      part of our business. The clinical programmes advancing the BrachySil&#8482; targeted
      oncology product as well as programmes relating the drug delivery applications
      of BioSilicon&#8482; are progressing well and continue to meet expectations.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">What
      is
      the status of your BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      collaboration with an undisclosed Top 5 global pharmaceutical company and have
      you entered into any new evaluation agreements? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      technical programme at the Top 5 global pharma was completed on schedule with
      successful results and discussions are still continuing as to the form of the
      next stage of our business relationship. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      also
      recently entered into another agreement with an undisclosed large pharmaceutical
      company to evaluate the BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      technology for certain drug delivery applications. In addition, there are
      ongoing discussions with other pharmaceutical and biotech companies with more
      news expected this year. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      phase
      IIb clinical trial for determining the optimal dose of BrachySil&#8482; in the
      treatment of primary liver cancer commenced in October 2005. When will interim
      results be made available? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      have been a number of patients treated at key centres in Singapore with further
      patients being recruited. Patients will soon be treated in Vietnam as
      well.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      key
      objectives of the phase IIb clinical trial is initially to determine the optimal
      radioactivity dose implanted per cubic centimetre of tumour, as well as the
      maximum radioactivity level implanted per patient. Three dose levels will be
      evaluated and the data from the cohort of patients receiving the optimum dose
      will lead directly into the generation of pivotal clinical efficacy and safety
      data. Information about the progress made through the phases of this key trial
      will be provided during 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      phase
      IIa clinical trials of BrachySil&#8482; for the treatment of eight patients with
      advanced, inoperable primary liver cancer was concluded in early 2005.
      BrachySil&#8482; was found to be both safe and tolerable and all eight patients had
      significant reductions in the size of their tumours. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">When
      do
      you expect to commence human clinical trials using BrachySil&#8482; to target
      pancreatic tumours. Could you outline the progress you&#8217;ve made so far?
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pancreatic
      cancer represents a further important clinical indication with a high unmet
      clinical need. Plans are well advanced in finalising the details of the clinical
      protocol and the clinical centres of excellence have been selected and have
      agreed to conduct the work. Furthermore, interaction with regulatory agencies
      and submission of clinical trial protocols are well progressed. An announcement
      regarding the commencement of the clinical programme will be made in the second
      quarter of this year. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      October 2005, pSivida Limited signed a licensing agreement with Beijing
      Med-Pharm. The licence included upfront and milestone payments in excess of
      US$2
      million. What progress has been made to date? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      have
      been receiving these payments to schedule. Currently, we are negotiating the
      terms of the Manufacturing Supply Agreement to finalise local manufacture in
      China. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      May
      2005, you announced successful completion of the first stage of a proof of
      concept study in collaboration with Clinuvel Pharmaceuticals Limited, (formerly
      known as Epitan Limited). How are you progressing in the evaluation of
      BioSilicon&#8482; as a delivery platform for Clinuvel&#8217;s lead drug CUV1647 (formerly
      known as Melanotan&#8482;)? </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinuvel
      has extended the work programme and the next stage of technical collaboration
      has been initiated. New technical work is focused on loading a hydrophilic
      peptide into BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>
      TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      particles for injection. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">How
      has
      the ADR programme on NASDAQ performed since the listing in January last year?
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>MD
      Gavin Rezos </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
      are
      a total of 768,000 ADRs that are outstanding and tradeable as at the end of
      February 2006, representing 7,680,000 ordinary shares that have moved to the
      United States from the Australian market. There are also 16.5 million ADRs
      issued to former CDS shareholders in the United States currently held in escrow
      for periods of between six or nine months from the date of the closure of the
      acquisition. Accordingly, the total number of ADRs outstanding represents 44.6
      percent of the issued capital of the company as at the end of February 2006.
      The
      completion of the CDS acquisition has resulted in a significant shift in the
      proportion of shareholders domiciled outside of Australia. There is also an
      ever-increasing shareholder presence in the UK and Europe. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>corporatefile.com.au
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Thank
      you
      Gavin. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div>&#160;</div>
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="100%">
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      previous Open Briefings by pSivida, or to receive future Open Briefings by
      email, visit www.corporatefile.com.au.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information about pSivida, visit www.psivida.com.au or call Brian Leedman,
      Investor Relations Manager on +(61-8) 9327 8920.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSIVIDA
      DISCLAIMER:</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      This
      announcement does not constitute an offer of any securities for sale or the
      solicitation of an offer to buy any securities. Any securities offered may
      not
      be or have not been registered under the US Securities Act of 1933, as amended,
      and may not be offered or sold in the United States absent registration or
      an
      applicable exemption from registration requirements." </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases. Although
      we
      believe that the expectations reflected in such forward-looking statements
      are
      reasonable at this time, we can give no assurance that such expectations will
      prove to be correct. Given these uncertainties, readers are cautioned not to
      place undue reliance on such forward-looking statements. Actual results could
      differ materially from those anticipated in these forward-looking statements
      due
      to many important factors including: the failure of the results of the Retisert
      for DME trial to be a good indicator of the results of pSivida&#8217;s ongoing Phase
      III Medidur&#8482; for DME trial; failure of the Medidur&#8482; trials in DME to show a very
      similar improvement in visual acuity and diabetic retinopathy severity score
      as
      Retisert&#8482; for DME; inability to recruit patients for the Phase III Medidur&#8482; for
      DME trial; our failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
      expected revenues and the combined entity&#8217;s inability to develop existing or
      proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
      arrangement to provide faster royalty growth. Other reasons are contained in
      cautionary statements in the Registration Statement on Form 20-F filed with
      the
      U.S. Securities and Exchange Commission, including, without limitation, under
      Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or
      written forward-looking statements that may be made by or on behalf of pSivida.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CORPORATE
      FILE DISCLAIMER:</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Corporate File Pty Ltd has taken reasonable care in publishing the information
      contained in this Open Briefing&#174;. It is information given in a summary form and
      does not purport to be complete. The information contained is not intended
      to be
      used as the basis for making any investment decision and you are solely
      responsible for any use you choose to make of the information. We strongly
      advise that you seek independent professional advice before making any
      investment decisions. Corporate File Pty Ltd is not responsible for any
      consequences of the use you make of the information, including any loss or
      damage you or a third party might suffer as a result of that use.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0J*17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`V.C`S.C(R(#(R.C0P
M.C,U``````.@`0`#`````0`!``"@`@`$`````0```2"@`P`$`````0```%L`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)7`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"@`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DEF9[[L.X7U/>6.(-M;CN9!.WV[G?H_[#5#S&<88
M>Y($P!]=?HQ_>2!>CIJGU'JV!TUC3E6199/HX[`7W6D?F8^-7NNN=[OS&*IU
M>^W'M'H9#@]VKZI!V@B*SMC<W?LL4M,?"_:)_2Y;ZFM;8\-+AO+?T;'-:'^E
MO]_IJ'[_``&7+BE"4?8C[F27IX>#AXQ7]Y1B:!!&NB%M7U@ZFP69%IZ)C&?T
M%)9;DEO8WY-C;,?&=_P6.R__`,-)_JG;FW=,?;DWOR:'WV_8+[@!:_%!VX]M
ML-KW^KM?;59L_24>DB_L^W,Q'8]MUGI7DMRB7$/<P?X&KW.;3ZT[;7L_P/\`
M-^G9^EJT;+*,:@V6N9114V7.<0QC6CQ<8:QC59Q3,\<9F/#Q"^'>EG#4KLZ=
M>Z1)4G=:Z.U]%;L['#\H!V.TVLFQKCM8ZKW?I&O=[6;5'JF;=CFJJ@`V7$B3
MK'#1']9SDW/FA@QRR3OAC7RCBD>+TQ$0NCZC0;Z2S:,CJ=.6VC*9ZK'_`.$K
M;HWSW`#^UN1[?5^WU1D-97MUQR1N=]+W-4<.:C./$(3!$QBE"8X)P,NOJ_1_
MN)X?'Q;:2!CYV%E66U8V15?9CG;>RM[7N8Z2W;:UA+JW>Q_TU0ZCU#&SND9A
MZ7U3&ILK;!S&V,<REQ/TK7`N:S^VK*TR`%NLDL[H]KJ>B46YN=5F&NLNNSVN
M;Z3@"2;?4'Z/8UJP?K+]:[J,CI!Z)ETW8V9>ZK(>S;:##L9NS>T_HW;+GI4M
MED$8\1\-.OJ>O25?,ZA@8#`_-R:L9CC#77/:P$CLW>6[D^)FX>;5ZV'?7DU3
MM]2I[7MD?F[F%WN276+J]7__T/55E=6MQ[,BO!#@<RRI]K*@'.=Z=99NL]C2
MUK=[FL_2/K]3_!;U:ZKU*CI?3[L_(DUTB0QHESG.(954P?OW6N94Q5>@]+R,
M.JS*ZA8+NJYI#\RP?0;$^EB8\_1Q<5K]E7[_`.DO^G<H\^&.;%+'+Y9BE"1$
MA7FY5M.'6'V4LL9E95KK\Q]TE[GQMK;ZC_\``T,_18]3/957^8KSKSE8>-AT
ML>Z`SU7[3`V_F_YWYZ?ZR7U5?96.)-MCGBJE@W6/(#?;34WW/V_GN_FZO\+9
M6M#IOK_8ZO5#0-C0QK#N]H'+K(;N<[^1_P!-9,.5S9.<YF,Y^F<(0EDX.'WA
M&,.*,/5_X8OXHB,0!MT_=\T^/5Z5360`1J8U$G4]FK-^M?\`XFNI?^%[/R+6
M63]:_P#Q-]2_\+V?D6S"(B(Q&T0`/HQ9/EEY%\]ZETCI]?U!P>K5U!N?;:!;
M?)+G";:]AD[=C/2K]-G^#7I.5AMS\6E[G;+@T%KNTN`+FD+@<?HOUHZW]5^F
M]/Q_LQZ6YQM9:2YEC(=8S9>WW>IL<^Q[/1_G%WO4.G/N%+\8AME&C0=-!&W7
M]YNU0\Z.+!./M>_>^*^$R'%^C_6C\S%RHHW7`#&&M;GA0XV;F8V2W%S]=\"M
M^A_DM]S?IM<I9/\`RYB_U#_Z,3,PL_(RJ[\TM:VF"UK>Y&O_`%7TD>[$N?U.
MC):!Z5;8=KK/O[?VEGPAS$L0B1DE"',8I8O>_G_9C(<?N?U8MNQ?38W6SR61
M?_S=^N?5+1#*.H8+\M@[&VL;O\]UE5__`&ZJ_3.G##_Q8YMSA%F:QU[OA+:J
MO_`ZFO6K]>_JOU'KCL.WIPK-E(M9;ZCBSVO]-U<>U_T',>M;K/2++OJS=TC`
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M[CZRY(JLPFW].RL_%;:,@/PFFQ]=U#F68_JT#Z=-GO\`^VTS<_ZR]481A80Z
M12[C*SX?=!GW5=/H=]-O_=G)K_XFQ?.:2+$;XCO76GZ5Q?J[B8[#NNOR,BP$
M7Y5UFZVP$SL?9'LH;^;C4>EC?\$KV-BLQFEK'O<TQ#7NW!H'9G[J^7$E6_H_
MWCI]XKQX^&O^BRQ^73Y7ZJ5?/PJ<_"NPK]WHY##6_:8=!_=<OEU)6$&J-[=7
MZ?Z7TW'Z5@4]/Q=WH4`AF\[G:DO]SO[2MKY5225&J%;5IY/U4DOE5))+]5)+
MY5224_522^54DE/U4DOE5))3_]G_[0\,4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`$@````!``$`2```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-
M!!X```````0`````.$))300:``````,]````!@``````````````6P```2``
M```$`&P`;P!G`&\````!``````````````````````````$`````````````
M`2````!;``````````````````````$`````````````````````````$```
M``$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$`
M```$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO
M;F<```!;`````%)G:'1L;VYG```!(`````9S;&EC97-6;$QS`````4]B:F,`
M```!```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U
M<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-
M875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM
M9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N
M9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````6P````!29VAT
M;&]N9P```2`````#=7)L5$585`````$```````!N=6QL5$585`````$`````
M``!-<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q4
M97AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!
M;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R
M=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB
M9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90``
M``ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,
M8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X
M0DE-!!0```````0````".$))300,``````EX`````0```(`````H```!@```
M/`````E<`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--``'_
M[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.
M#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``H`(`#`2(``A$!`Q$!_]T`!``(_\0!/P``
M`04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!
M``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H`#`,!``(1`Q$`/P#U5))9F>^[#N%]3WECB#;6X[F03M]NYWZ/^PU0\QG&
M&'N2!,`?77Z,?WD@7HZ:I]1ZM@=-8TY5D663Z..P%]UI'YF/C5[KKG>[\QBJ
M=7OMQ[1Z&0X/=J^J0=H(BL[8W-W[+%+3'POVB?TN6^IK6V/#2X;RW]&QS6A_
MI;_?Z:A^_P`!ERXI0E'V(^YDEZ>'@X>,5_>48F@01KHA;5]8.IL%F1:>B8QG
M]!266Y);V-^38VS'QG?\%CLO_P##2?ZIVYMW3'VY-[\FA]]OV"^X`6OQ0=N/
M;;#:]_J[7VU6;/TE'I(O[/MS,1V/;=9Z5Y+<HEQ#W,'^!J]SFT^M.VU[/\#_
M`#?IV?I:M&RRC&H-EKF445-ESG$,8UH\7&&L8U6<4S/'&9CP\0OAWI9PU*[.
MG7ND25)W6NCM?16[.QP_*`=CM-K)L:X[6.J]WZ1KW>UFU1ZIFW8YJJH`-EQ(
MDZQPT1_6<Y-SYH8,<LD[X8U\HXI'B],1$+H^HT&^DLVC(ZG3EMHRF>JQ_P#A
M*VZ-\]P`_M;D>WU?M]49#65[=<<D;G?2]S5'#FHSCQ"$P1,8I0F."<#+KZOT
M?[B>'Q\6VD@8^=A95EM6-D57V8YVWLK>U[F.DMVVM82ZMWL?]-4.H]0QL[I&
M8>E]4QJ;*VP<QMC',I<3]*UP+FL_MJRM,@!;K)+.Z/:ZGHE%N;G59AKK+KL]
MKF^DX`DFWU!^CV-:L'ZR_6NZC(Z0>B9=-V-F7NJR'LVV@P[&;LWM/Z-VRYZ5
M+99!&/$?#3KZGKTE7S.H8&`P/S<FK&8XPUUSVL!([-WENY/B9N'FU>MAWUY-
M4[?4J>U[9'YNYA=[DEUBZO5__]#U5975K<>S(KP0X',LJ?:RH!SG>G66;K/8
MTM:W>YK/TCZ_4_P6]6NJ]2HZ7T^[/R)-=(D,:)<YSB&55,'[]UKF5,57H/2\
MC#JLRNH6"[JN:0_,L'T&Q/I8F//T<7%:_95^_P#I+_IW*//ACFQ2QR^68I0D
M1(5YN5;3AUA]E++&965:Z_,?=)>Y\;:V^H__``-#/T6/4SV55_F*\Z\Y6'C8
M=+'N@,]5^TP-OYO^=^>G^LE]57V5CB3;8YXJI8-UCR`WVTU-]S]OY[OYNK_"
MV5K0Z;Z_V.KU0T#8T,:P[O:!RZR&[G._D?\`363#E<V3G.9C.?IG"$)9.#A]
MX1C#BC#U?^&+^*(C$`;=/W?-/CU>E4UD`$:F-1)U/9JS?K7_`.)KJ7_A>S\B
MUED_6O\`\3?4O_"]GY%LPB(B,1M$`#Z,63Y9>1?/>I=(Z?7]0<'JU=0;GVV@
M6WR2YPFVO89.W8STJ_39_@UZ3E8;<_%I>YVRX-!:[M+@"YI"X''Z+]:.M_5?
MIO3\?[,>EN<;66DN98R'6,V7M]WJ;'/L>ST?YQ=[U#IS[A2_&(;91HT'301M
MU_>;M4/.CBP3C[7OWOBOA,AQ?H_UH_,Q<J*-UP`QAK6YX4.-FYF-DMQ<_7?`
MK?H?Y+?<WZ;7*63_`,N8O]0_^C$S,+/R,JN_-+6MI@M:WN1K_P!5])'NQ+G]
M3HR6@>E6V':ZS[^W]I9\(<Q+$(D9)0AS&*6+WOY_V8R''[G]6+;L7TV-UL\E
MD7_\W?KGU2T0RCJ&"_+8.QMK&[_/=95?_P!NJOTSIPP_\6.;<X19FL=>[X2V
MJK_P.IKUJ_7OZK]1ZX[#MZ<*S92+66^HXL]K_3=7'M?]!S'K6ZSTBR[ZLW=(
MP`W=Z#:*`\[1#=K6[G0[\UJV;V:7MRXLFGI`EP>>1Y'J]KZ_\5^`UAAMKJVO
M'BT.LMV_Y];$/ZS]&Z9TK*^KIP:!2Z^QOKN$R\L?BEC[)^E9^E?[UNY7U5SL
MOZCT=%>:V9^.&N:-Q-9>UQ=L]3;^?6YS?H+/S/J]]<>JGI-N>S%;^SK&C8QY
MWEH=4ZR^UT/K]1_H?S525K)XY57"2>''6GR\)]3=^M^/]6AU;$RNM67Y5^PU
MXO2J07^I)^ELK:+-UECF?3NK];TO^#53_%VWTNK];H92[%J#F$8KSN=7#KFM
MJ>_W;GUL]GTE<ZKT3ZQU?6S]N])KQ\IME(J:W)<6BK38Z/SV_O[Z?])?6C?5
M/H'6>E]4ZGE]3=58<TM<+:C])VZQ]CO2VM]+^<2Z+^&1S"7#52.M?H\._$__
MT>X^LN2*K,)M_3LK/Q6VC(#\)IL?7=0YEF/ZM`^G39[_`/MM,W/^LO5&$86$
M.D4NXRL^'W09]U73Z'?3;_W9R:_^)L7SFDBQ&^([UUI^E<7ZNXF.P[KK\C(L
M!%^5=9NML!,['V1[*&_FXU'I8W_!*]C8K,9I:Q[W-,0U[MP:!V9^ZOEQ)5OZ
M/]XZ?>*\>/AK_HLL?ET^5^JE7S\*G/PKL*_=Z.0PUOVF'0?W7+Y=25A!JC>W
M5^G^E]-Q^E8%/3\7=Z%`(9O.YVI+_<[^TK:^54DE1JA6U:>3]5)+Y5222_52
M2^54DE/U4DOE5))3]5)+Y5224__9.$))300A``````!5`````0$````/`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<`"```
M``$!`/_A&(IH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME
M="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^
M"CP_861O8F4M>&%P+69I;'1E<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM
M;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R
M+C@N,BTS,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@
M>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D
M9CI$97-C<FEP=&EO;B!A8F]U=#TG=75I9#IC.3@U,#4P9BUB83%E+3$Q9&$M
M.31E,RUA.#,T-#$Q9C@P8C8G"B`@>&UL;G,Z97AI9CTG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF.D-O;&]R4W!A8V4^,3PO97AI
M9CI#;VQO<E-P86-E/@H@(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ.#D\+V5X
M:68Z4&EX96Q81&EM96YS:6]N/@H@(#QE>&EF.E!I>&5L641I;65N<VEO;CXV
M,#PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$97-C<FEP=&EO;CX*
M"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED.F,Y.#4P-3!F+6)A,64M
M,3%D82TY-&4S+6$X,S0T,3%F.#!B-B<*("!X;6QN<SIP9&8])VAT='`Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\G/@H@(#PA+2T@<&1F.D-R96%T:6]N1&%T
M92!I<R!A;&EA<V5D("TM/@H@(#PA+2T@<&1F.DUO9$1A=&4@:7,@86QI87-E
M9"`M+3X*("`\(2TM('!D9CI#<F5A=&]R(&ES(&%L:6%S960@+2T^"B`\+W)D
M9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED
M.F,Y.#4P-3!F+6)A,64M,3%D82TY-&4S+6$X,S0T,3%F.#!B-B<*("!X;6QN
M<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO<#I(:7-T;W)Y
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!A8F]U
M=#TG=75I9#IC.3@U,#4P9BUB83%E+3$Q9&$M.31E,RUA.#,T-#$Q9C@P8C8G
M"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\G
M/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B`@
M/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF9CI84F5S;VQU=&EO;CX*("`\
M=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F.EE297-O;'5T:6]N/@H@(#QT
M:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U
M=6ED.F,Y.#4P-3!F+6)A,64M,3%D82TY-&4S+6$X,S0T,3%F.#!B-B<*("!X
M;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX
M87`Z0W)E871E1&%T93XR,#`U+3`W+3(V5#(Q.C$S.C(S+3`U.C`P/"]X87`Z
M0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`P-2TP-RTR-E0R,3HQ
M,SHR,RTP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A
M=&4^,C`P-2TP-RTR-E0R,3HQ,SHR,RTP-3HP,#PO>&%P.DUE=&%D871A1&%T
M93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD
M;W=S/"]X87`Z0W)E871O<E1O;VP^"B`@/"$M+2!X87`Z1F]R;6%T(&ES(&%L
M:6%S960@+2T^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T
M:6]N(&%B;W5T/2=U=6ED.F,Y.#4P-3!F+6)A,64M,3%D82TY-&4S+6$X,S0T
M,3%F.#!B-B<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z
M<&AO=&]S:&]P.F$Q,CEF,C,V+6)A,64M,3%D82TY-&4S+6$X,S0T,3%F.#!B
M-CPO>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z8SDX-3`U,&8M8F$Q92TQ,61A
M+3DT93,M83@S-#0Q,68X,&(V)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G
M/"]D8SIF;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*
M/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&
M24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S
M<$U31E0`````245#('-21T(``````````````````/;6``$`````TRU(4"`@
M````````````````````````````````````````````````````````````
M```18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP=```
M`@0````4<EA96@```A@````49UA96@```BP````48EA96@```D`````49&UN
M9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0````D
M;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P`
M``@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````
M$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR
M+C$`````````````````````````````````````````````````````````
M`````````%A96B````````#S40`!`````1;,6%E:(```````````````````
M``!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:
M(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI
M96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````
M````````````````````````````````````````````````````9&5S8P``
M```````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E<V,`
M````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ``````````````````````````````````!V:65W
M```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`
M4````%<?YVUE87,``````````0````````````````````````*/`````G-I
M9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`
M-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D
M`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!
M'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y
M`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"
MA`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R
M`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$
MF@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E
M!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'
M=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE
M"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+
M(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`
M#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`
M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;
MLAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^
M'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC
M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=)
M)WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTK
MT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L
M,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TU
MAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR
M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`
M9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B
M1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,
M<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'
M4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9
MN%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J
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M,XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1
MDGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;
MKYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4X
MI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:O
MB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"
MNCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$
MSL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^X
MT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;
M@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?
MYZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGS
MI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?__
M_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!
M`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#_\``$0@`6P$@`P$1``(1`0,1`?_=``0`)/_$`:(`
M```&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!````````````
M!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$4
M03(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W
M1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY
M>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7F
MY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R
M811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS
M@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6
MIK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI:
M:GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=<6M;G^OOV//KW^'KW-OQ?\`WCW[@34XZ]BN.@R[7[DZMZ-V
MCD-]=N;ZVYL/:N+ADJ*O+;BR=-CX@D:EW6GBF<3UDFE"1'$KN;<`^[)'+*P2
M-"W^K'17NV\[5L5I)>[M?1P6RBI+$#`]!Q/Y`GJE'<'\XSM7Y`9^OV9_+@^)
M>^OD`U'4M!_I:W9$VT>KBJ,WDGIFRRXNNKH$0`ZDD7]0X]FJ;;'"%>\N-*GR
M''_5]G4*WOO!O&]W$]C[=\IS7\JTI-)V0FOVZ3CYD=`+O7^:1_,L^%O:/4Q^
M?'Q\ZMQW2W:>YZ+;@S7655)+D\+45TQIUIQ42Y6L@DJX'D5RD@.I%)!^GM0+
M#;[E";.9@]?/^6*>?0>G]T/<_D[<=N/N!L%JFU3MQAX@#B`VMNX#N((I0'/6
MS1BLA3Y;&8[*TI)I<G04F0IBWZC!6T\=3"3_`(F.4>R`BA(ZR;AE6:**9/@=
M0P^PBHZG^_=.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__T-_CW[KW7O?OGU[KC?\`WU^?]M]?>@>%<'KQ^7'K
MNX]^K7@,=>^WKU_\.?K;_C?OQ-.O'Y=>O_3GWZHI4\.O==:O\/\`;\<_['WX
MFF?+KQJ.N,DB(KO(RI'&I=Y'(58U4%F=F:P554$DG@#WO_#U5BH!)\O]5>J6
M?F-_.$V-U=NZ?X[_`!(V?D_E9\J,C-)BZ+:>PQ_%MI[3K)E\$.0W3N+'BLHE
MBI*R1?+"&&D*=3`>S*WVXR#Q;A@L7SX_L\OMZAWF[W;LMNNFV+E2U;<N8V[0
ML?=&A\B66H:AXJ.'XB!T`_3?\IONGY5;RQGR&_FP]F5G:.X14+E=L_&[;63D
MH>J=D%6C>FI:^BHY9*'*CQ`K)$MAR06/MU[Y+8&*Q4!:9-/\'F3Z$_ET']F]
MJ]YYIO(]_P#=#<6N)S0K;*Q$:?(@$J%/FB^6&8]7[[,V5M'KS;>,V?L7;F'V
MEM?#0BFQ>`P5#!C\900+8".GI:=5CC6P_I<^REI'D8N[DMZG_9ZGBPL++;+6
M.RV^U2"U3X40`*/L`ZUU_P"9;]O\[OYBWQ)^!VSO-F=O=09RF[K^05?1(67:
M5%05)^PHIV6Y,U53/"UB4XD'XN?9U9@VEE+=-AC\/S_U'_!UCU[D_P#(Y]P.
M6.2+)/$M;9_%NF'&/_.-!`;/X@/.HV1\?1PXZ@H<?3@+!04E-10*!8"&EA2"
M,`#Z`)&/9*<DGK(Z)%BCCB3X%4`?8!3J9[UU?KWOW7NO>_=>Z\>![]U[KJ_T
MO_Q6W^Q]ZKPQU[KU_P#?7][QPKGKQ^77=_?NO==7_P`/>JYH1UX9ZZU?3B_/
M]?\`>?\`'WZO7OGY==W_`.-?X^_`^O'KW7?O?7NO>_=>Z][]U[KCJO\`3_8C
M\_\`&_?J'TQUJM>&<]=@W_P]^ZWYGKOW[KW75_\`>/?NO=>O_MOZ^_=:\R.O
M>_=;Z[]^Z]U[W[KW7O?NO=>]^Z]U_]'?X]^Z]UQ8'BWX]Z-/,=>_+H'>Y.P]
MS]<X*BRFU]DU>]ZNIKX:6>AHVE5J>&0D/4%HD=@$_P!:WO'7[QGN]SS[/\L;
M;OG(WMO+S)>RW*QO$AD'AH>+$QH[5]*BGJ0,]&^T;?:W\TD=Q>"$`<33_*>@
M@VG\L\74;AHML=E[2RW7&2R9C6AFR:L]`[2'2IFJ)`GAC+^D,0>2/>._(/W_
M`+:+GFW;>2?>OV_O>3MWO2JPO/5H"6-`7=@C(A;MU::5(!Z-;OE61;<WFW72
MW$:@U`XC[`./1LJZOAH<76Y5]4U/24,^08P?N-+!3T[5)\(_MLZ)Z1^2?>?N
MZ[M:;7LFY;Z^J6RM[62X.C)9(XS(=%.)95[:<21T%EC+R+%P8L!GU)IT3W_9
MXNK5)$F%W?"QO=9<6(V]/^T^;@GWSHD_O1_8N+MGY<WY)`>#0Q`_]7>A=_4G
M=&K26/3]IK_@Z]_L\757U_A>Z1:WUQR7)_`_SW)/X]MC^],]A,UV'?:_\T8O
M^MO6QR3N>098A3YG_-T77Y#5FU/GK@<;T/@>W>XNDL?N2H:FR>1V1A(X*[-0
MLI>6BFSZ9&CJL73O#"R$J2#<_P!?<G^T/]X5[0>Z'/?+_(7+_+&\'=]SF\**
M26%1$C:6:KE)&*K13DBE:9Z`?N![5;MO^S26[\QR65LF7\'XG6HQJ)&/EYCH
M9OB]\*/BG_+OZSJUZ^VWB\94PPM5;N[.W'%#D=\;GKCK>6HK\[5":O\`)5R/
M801R"/41Q?GWE_[@>X?+O(?+.[<X<Z;O'8\NV2%W=CCY*H_$[GM4<233H.<C
M^W.Q\L)%9;+8*^XOAI6`,CGU+&I5?Z(-!U/J_E[N#+BIKNN^H-Q[KPD$LD,>
M5D$U-',Z?552&.8AKV%OQ[YLW_\`>%\X\Q+>[E[-^P.Y[YRRDA1;J3Q$5F'$
M%8DE((Q49(].IA7E2"'0FX[FD4QXK@T_,D=3OE?\NHOC3\=X>S)=L5&9[5WD
MN,VQU3U33K+4YC>'9NXX'7`[8BIXBE3X6J4/FEM:-5Y^OOI3[=;GNG./*W+F
M_;QM#;??75I'--`U:P,R@NA)`/:21D`^HZB#W$YH@Y(VRZN(5^IW!Y!#;1#+
M33-41J`/(TR>`Z!K^6M\(\E\9]G;L[;[BK/[U_*OY$9(;Z[IW;6`3U6+J:\R
M5..V-BZF0&HAQ>W:.:*GD2^EYX;VX!(OO[H3-HB'^+K@4\_G]O0:]M>2)>6[
M.YW;>G\7FG<#XD[G)2IKX2DYTK4`CU'RZL^'T]H.I0QY<.N_?NO=>]^Z]U[W
M[KW71^GOU*]>_*O22W/OO9^S8TDW3N3$X-9!=!D*I(6DXXT(;N;V_`]QYSS[
ML>VWMG`EQS]SGM^U1/E?J)0A;[!Q/Y#I7;65W>$K:VSR'Y#I%8WO[IW*U245
M%V!MYZF1M$435@0RO_2,NH4G_8^XSV3[W/W;N8+Z/;ML]W-G>]D8!5,NDL3P
M"U`!_;TKDV+=HE+O82:?LX="['+%-''+#(DL4JJ\<D;!T=&&H,K+<%2#]1[R
M'@N+>Y@AN+:99+=U#*RD,"IR"",$&O15ITLRL#7T].N%1.E-!/4O<QT\,LT@
M')*0HTC:1^39?=;VZCLK.\O)Z^!#&TC4&:("QI\Z#'7E!)5/,FG15:;YC=4U
M>=@V[%3[F^_J,M%AHF.+'A^[FG6G0Z_."(?(XN;?3\>\";;^\=]AKOFJSY/@
MV_>OWE-?):J3;H$\2201`D^+73K(J:5IFG0I/*.Z"`SLT8C"%N)X`5].C8@W
M"G^H_/\`C8^\_5(:C`'(KT%NN7N_6NO>_=>Z][\>'7NJ[/G/_,Q^/?\`+ZK-
M@T?=]%OJKF['@RM1@3L[`+FD2/#S4\-2*UFJZ40,6J5TCDD>UUGM\]Z"T0%%
M('GY]1QSW[G\O^WTNW0;U#.SW*NR^&H.$(!J2R^HH.)Z7WP@^=_3/SYV!N7L
M?I6DW=28':VXH]LY)-WX=<-6MD9*&/(*U/"M14B6#P2CU7_5Q[I=6<EH8_$(
M)85Q\C3HPY(Y^V7GZSOKW94F6&WE$;>(H4ZBH;%"010^O1U?:3H;]<#;\?[:
M_O>:8X]>!S3S/1=>S_EQ\9>EMR?W/[9[QZYZ^W3]I!7?P'=&XJ3&9+[.I3RT
M]0::8A_#-'RI^A'MV.UN+@5BB9OLZ#6Z\X\J[%=&SWC?K:WNJ`Z9'"M0Y!H?
M7RZ%C8'8>R.U-IXK?77&Z<+O/9^;227$;CV_61Y#$Y&**5H9&I*N+T2JDJ%2
M1^1[;>.2(^&ZD.!Y]&^V[E8;O:0[AMEW'/9R?"Z'4I`]#Y]+7W7I=U[W[KW7
MO?NO=>]^Z]U__]+?X]^Z]U[W[KW7%D5@055K_AA<?[8W]U=$D&ET#+Z$5_P]
M>ZJ2[[V53,F>R4&([-J\EALC4RKF=P_P'^[U)0R5#3,U,U)4'(B%)V&BZW`M
MQ[^>?[VGMK:1MS3S!:\O<]S[QMEW*YO+[]W_`+OBMVE+$1F*0W&@.W95:@4Z
ME?8KMO\`%XFEM0I`[5U:B:>=1IK3HYOQ,WO5;UZDH8,I+]W6[;F?;]3+,3+)
M4QPH'BDF\@)<.DNGF_"^^F?]WY[HWGNA]W[;+7>)S/N.S2M8.SG4[HJAT:0G
MXB4>F:U``/0-YILEL]U=HUHD@U8X?.G23^9FW\#3]0SY*##8VGR%/F\1'!6T
M])!3SQ)-4Z9U#PQHS"5>"#Q[CG^\MY/Y4M?N[3;S:<MV46ZP;K9K'-'#'&ZK
M))1Q5%!(88(/2SD^XG?=?":9M!C;!)/`8_9U4[)]%M]"RKS_`$8^KZ<W]_/:
M*5&H_/J5A52&KFG5^FQ-O8'%[5VNV/PN,HV3"8J1'@HZ=)A)+0PN[B81^0N[
M,23>YO[^NKVFY/Y1V3D+D1]DY;LK=AM5JP9(8PX9X$9FUZ==22:FM<]0+?3S
MO<W2M*Q&ML5-./1#/FYO&OR.YMI];43RO1)'%E:ZDII-+UE162FDCI9!<1OI
M6Q4,;!S[Y0?WH'N3NV[\Z\B>R^UR2MMZ(EU*D34:2:9S$D9&`Q"K50QTAB#@
M]#GDRTC2VNMP>@:ND$^0&?\`53H3/C;M*BV_FXX*7$=E8=:#%SR3T6XUP!V_
M/6U,0%2]*N/GDJC+<#1K`Y]S-]R3V[VKE/FJUMK+8.>-N-M92&2+<Q8?N]II
M5I(Z?3R-*6P"I8<>/1=S)=O/;LYDMV!<4*:M8`]:XH?ETO,?\?Z/>/=</?G:
MM/3YO/[3I:C"]3[;J46HP^P<?4!(\EEZ:FF#03[@S+PQR_<.K24S"T3*./?5
MAIUCMUMH1I7\1'F?(8\OEU#L?+D=]OZ\Q;N@DN805MT.5B4_$P!P7:@.KBOE
M3HT=Q>Q^IY']?K]?Z?7VFIGH6>>FO<>N7^/]/I_KGWK&#UZM!\NNCJ'(M^;_
M`%][/EQZM@\:UZZ'`N2`+@\DVO\`ZY_K[UP''JI]0>NS_O/_`!'OWF*''6SP
M-.D#VAO6#KS8FXMW3@,<50.U.A(L]9+^S2BQ!U6G=3;\@'W$?OI[G6WL_P"U
M'.7N#.FKZ"U)C7UE<Z(A\^]E)'F`1TOVRS;<+ZVM%_$V?LXGJD>6HWMV[O`&
M>2NW#NG<%4SQ4OE=XXM9'IBA+B&*FIE-SP+#W\O=YN?NE]XOW("2S7.[\W;K
M<]J`D@$G\*DZ8XT&:"@`'4TJEGM-JQQ';1KD_9PSYUZ7F_\`XX]F];X5-Q9W
M&T\^(C*"KJL7(9&QSN39JG2WD1+CEENH_K[ECW>^YC[X>RG+<7.7,.RK)LB%
M?%EMW\3Z<GX?$`[@,?&`5'F1T@V[F';=RG^DB:DM:BN*CS_XKH=OB!WAE<;N
M2FZRW'D9*_#9NT>VY*J9YYZ#(!25HHY'+-]M-&I;U-<-:W]/>5_]W3]Z7?\`
M:.<K+V3YSW::ZV'='T6#2$N\%S2HB5C6D4@#8)PP%,8Z(^;=DB:WDW2WC"RH
M>^G`CU^W_)U9W6T_W=)54X8K]S35%.&^N@S1/'K_`-AJ]]R]RM?K]NO]O#Z3
M/#)'7TUH5K^5:]1HCA&1P*T(/1`J#X25E%NVEW+_`'U5EIMPP9S[?[6S,(:J
M.I\.H1_VM%O?)/;_`.[&W&RY^VWG/_7'B86^ZQ7>CPC4B.99M-:?$2M*\.AT
M_.8:U>`VO%"I-?E3JP9+Z0/K8`7_`*V^I]]=P**JD9``Z`=0<@8Z[YMR+_UM
M?W<8''/6JTS\NN)O;Z<D\VY_V/O6:UZW4?:0.N_J.?\`6_V!X_U^?>^%`.'6
M^%.J:_YJ_P#*NR?\QW)]09#']IIURO6%+N"FFA>@-:,I_&JBCF5@1#*$,'VI
M'XOJ]F>W[D;%955:ZB#^SJ%_=7VI?W(NMHG&Y+`EM'(I#`FNLJ:BGF*?SZ%G
M^5M_+WK_`.7=U%OCK*O[!'8DF\-YP[J7(I2&C6A2+%0X[[0(8XM6HQ:KV_/N
MFX7JWDD;JA4*M.C;VN]O)/;S:]SV^2^$_P!1.),"@6BA:>1S2O5G=_Z?TXM_
M3_>[^R_(X\>I1K^SKQL21]2+FUQ<?TX!O8^_<<$8ZT,5SUH/_P#"C2&)_P"8
M0Y8,2>K=F?221;VQ"<65@H(]C38JFT3'F>N?OWDV=/<"Y*D9MK?Y_A^?6SY_
M(]18_P"69\;U6^G^$;@(NS,>=R93ZEB2?8=W<?X]*/D/\'64WL8:^V>P$\:R
M_P#5UNK9N?\`D5O9;GSIU+O7&X!MQ<GZ$BY_UA?WJK5I3KV,==D?0_2W^]>_
M$5H"*]:H*U\^N7O?6^O_T]_CW[KW7O?NO=>]^Z]U6GW5@F:KW]'_``'MB?TR
MR+5MNS$_W7-R'\C8LTGW7VB_ZC7?_'WQ%^]#RPTE[[L1'E+G^8%'83'=;7]U
MG(-6M?!\7P1_!JU<,]21LLQ"61\>T%2*C00]:>M:5^?0?]*_(CK/XO?'[N/N
M7M_<,.WMB[+J9,C75,K?O5=48]%)C:&`7>>OKJ@+"@`(U.+V'/N4/[IMWNN5
M/<O;8F[X[N.5E)%%4JJZOVXZ#7NSOECRS8)O>ZMIM8U(%!4LWDB@<230?GT3
MOH/Y0_)CYK=6_(GY(=H;,KNN?C?N/<6S,+\9=K9,"GR<]%B,W/'F,_64[QQR
MU$N4I95)J5'AETV3A;^YW_O1X+6V^ZU+%#F[_?-EK/F1XIH?E\AQ]>HF^[WS
M+S1SES-S!S#NT!AY;DB"V<9%*%2=?'XZBE7%%)J!4"I\]K+];ZEO?DBQ'T/^
M/OYM!6M!PZR\-`*TS_GZV#-HW.U-L@C2/X!A^#SQ_#Z;Z?Z_O[#/;JHY`Y'R
M:_NBS_[1HNH!NJ&ZN?\`FHW^$]54?(XG)?)`TK05E:L?VE.*;&SI3Y!_&Z2:
M*6HD5XX)E^H)%@??`[[Z3MOGWPI[*2UN[D1301B.VD6.<A>X")V!5'J>TD$`
MYZD_ES5'R^2NE:URV17Y@9(Z.)\?\88-PYVH.*[)QUJ.%=>]-QX[-44MR1:F
MAHJ:!X95_)8D'WT8^Y_LDEMS=S5>-R[SM9>';H*[UN5M>Q/K)%(EAB0JX\R3
MT$^8)M4%N@FMFR?[-"I'VU)J/3HV@O\`3BWXM_O8]]"_S->@H:GSZY6YO[]U
M[TZ9=R3S4>WL]5TTABJ:7"Y2IIY5_5'/#0SR12#@\I(H/^P][4:G2O"HZ3W3
M-':W+H:.(V(/H0#3K0+I_P"</\V^O?EAE)=^_(3?68ZAV1W#D?[P;-IZBE`R
MNTL/E*=Y]NTUZ&R?=4<;QJ6-@6Y/L:)MEK-!(/IT&"*YK6G'^?7/Z?WFYSVK
MFQ5N^8+J3;X[@%HJC2R*Y#(,8U`4%>%>E;\P_P"9?_-,[ODR_>&U*3N#XZ_&
M5\M+#LI=I8O+X:E.'%3*<3DMRY&?&RK5U%12,C-4!T@))(X(]TL]OL8OT&5&
MDIDFA)KZ#R^SCTLYW]S_`'.WE6WW;S?6.QZR$6-'1-->TM)C4U//"D\*]6&_
MR.OYM7=/;G;L_P`6/D[O*K["JMR8S^(]9=@9N99MQ29*E70^VLE.HA2L6HIH
MGF1PEQIM_KH=VVR.)3/;H`5&:#RZD+V)]WMYWO<EY;YFOC.\M1%(Y_4#BG9\
MUIP)[JC/J=D?Y5XBNS'26[(<?&\T],E)6/#&K.\D-/4QM+I5`2="#4>/H/>"
M/W]>7]UYA^[)SY;[1`\L\'@S,B`EFCCF4O0#)TBK?8#UF[RO+'%O-MXGPFH_
M.G56W1?86/ZR[(P6\<E2M58V**JHZSQ@-)3P9"-8)*J,$>HTZW:PY-N/?!C[
MJ?N_M7L9[V<L<_;]8M<;/")(90H!9$G3PVE4&M6C!U`#)H0,D=2;OUA+NFW2
M6<3@.:,/RS0_;U<U#7;.[9V?708[(TF:P&X<=+25)II8WD6&ICL5EBN7IY@#
M>S`$'W]+5MO'MQ]X'VZW.RVC>8-RY2W>S>*7PW4N(Y10ATRT;CB`P!!ZATI=
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M8.`,\*GSZQA]SYMWL^2MYW#9+Z2WOK9/%U)\15*ZE'V]:VO\EO\`FB_*WN#Y
MH8/JCY%]T[@[#VIOS9M;B\)B,[/3M#3;OBF%3%4T^FG@;[D4]-*I`)X_'L^W
M2PB2VUQ0(I"@F@/K0]8U>RWNGS+NW.4&U[_OL]S;SAXT20K35AE84S6E1]G5
M^?\`.(^4.[OBC\(.Q=^]<[EFVIV;DJC%8+9&9I&C6KI*^HR%,];/3"0/JFBQ
MZO\`16X/LFVV$37*ZHPRJ#4'SQC^?60'O!S-><K<EWEUMEUX&Z2NB1N*5%6&
MHBOF%K3JFG^1+\N/G)\N?DYO(]R][;NWWU9UELB>KS6!R<T;4%;E]PQR4>#F
ME\='$&DHZN!G`+`^S?=[6VM(*)"HD8BA'E3CU"GL-S?SKSCS//)NO,-S/MEO
M;LSQN015R5C.!Q!4GH?O^%!'S*^37Q3S?QQIOCYVMG>MH-WT&[Y=RIA9(H_X
MI)CZO&I1M/Y*>:_A29P+$?7VSLEG!="<S1AB"./Y]'OWB.=N9N4KCEQ=AWB:
MUBEBE+B,@%BI6E:^@)Z,/_(/^3O?/RC^./:>[^_NQ,OV-N/"=FTV&Q64S$B/
M/1XM\!3534L92&$!&J'+?GD^T^\V\4$T*Q1`56M!]O0F^[_S5OW->P;W=[]N
M,ES-'=*B%Z5"^&"1CYYZ&3^<=_,$SGP*^.5#E.NX:.?N#M/+5NT=@35@BJ:3
M!U%/0?>Y'.5U&66604U$Q\!%@)K?6WMG;+-+RX/B#`'#U/I7H\]Y?<.7D'EV
M*2Q_Y*=VY2-J:A&`*LY6H\L+D=U.M1SH7^8%_-OWKV)6[OZ?[7[G[FS>!:/+
M[AVS)3UNY-GM3%]<=%EL=08PHE+.R:(XM:,UR`2?8FN;"PCCHT2`4IQ"G]M*
M]8@<L>Y'NSN6YO>;=NFX7(C[F4!I5(\@Z`A:?(4KP'0(_P`QKY<;C^:/>M'V
MGO?KK)=6[^PVS\-L_>NULE%-3-'FL'21T515T=%4HE914=3-&[)'+=PMKD^U
M&VVRV\`5)-25)'Y]!KW2YON>;^81N%_MK6]]X,:.#@%D`!P0"OV'AZGK=H_D
M@_\`;LWXW?\`:FS_`/[TF3]A+=_]SY?L'^`=9S>Q?_3LN7_^;O\`U<;HDG\Y
M#^<CN/XC[BA^./QOIL56]R5F*;)[PWGE`E;B]B8ZJ1X8*.FI(Y(Y#N#R$27?
M4D:D&U_:G;-I^J`FFROD/EZ_9T"_>;WIEY-E;8MA"_O2E'E/=H)K1%6H[Z9J
M30?;UK-S_/7^:EO&AK.SZ;O3Y.5^VZ&5C4;HP='F9-J8XQDZ@M?2X)\;'30_
MDF2R@7)]B`V.V"D1BCU>F*G[?/K%UO<'W9ND?<EWG<VMQW:_U-`'H66B"GH>
MK@_Y2?\`.[[OW!W;LSXX?+'<0[#P'9>1BV_LGLNL5/[S8S=-;HCQN.SU5>&&
MMH:Z56`<(#'Q]?R5[GM")&\]J@5!Z''[./\`AZF;V?\`?3>;W>+/ESFJY:Y2
M=PBR,/U%=B`NHC!2N"2!0D=;C_L+]9G=?__4W^/?NO=>]^Z]U[W[KW1*^^-D
M1G<=57Q[0W[N5-Q4+FIK,1OG(8K"4=4BB"&FDQ4,$D"JP`<B]FM_C[YC?>R]
MJ[6;G:^W*#VZYMWS]\VA:22UWVXM;&&10(TC:T2-D`-`Y6M&_/H9[#?$6NDW
M5O&8VP&B#,1Q)U5_GY=$&H^INK-[_P`>^/'RKVL]1USO')87,+0U52U)2P9K
M"9FFRU!)45@0ZJ.H>ECCE%M,BW4\'WB/]Q_W-NONI^]?,W(ONS:OM-AO]LD"
MO/B*%UDUI(SFE4;X-60#3J_N/RCM'N'R];V=Q&;BVCE$FE30FE,?/AD>8QT?
MGY68[;F)^.M/B=HTV)H-M8K(;:H,-086.GBQ=#CZ>H\5-3T$-*!!#3PHME5;
M``>\VO[R;<K'>?NNWFY;=?Q7-I)NUB5>-U=6'BG(920?V](.2+2*RW2"UBMA
M%#'$P50ND(`.`&*=51R7L@!Y\BB_T+"_-_\``>_G87X@:8ZF"ND`C)ZOFCW?
MMW9G7^%R^X<M18VDH]L8R8M4SHCR^/&TQ$<,;$/-*S$`*O)O[^M2'W$Y-]L_
M:/ECF#G'F"VL;&VV.U<^)(JLU+6,A44G4[,:`!02?LSU!+6=S>7\\<,)+M*W
M#R[CQ]!U5C2QYOMWM?<79B[3S.:VL^5J)6I\7D9\+6I$$$%-%29"))98)@8P
MQM<V/O@M;6O,OWAO?WF[WKA]O]UW3D>3<I)&CM+E[*4(%T1+#<H'96%%8TJ<
MFO4H%H]KVFVVTW<<5T%`J0&SQ-1C'5C?0NUHL/@<AF#A]V;?J\O5M%)B]U;H
MK-R3+!2,?!4025<<1IUG\AX`YM[[/?=-Y$AY;Y5W;F-^6^8-HO\`<)RC6NZ;
MI-N3A(3V2QF55,8?4<#C3Y=1WOUR9ITA\:&14'Q1H$&?+'&G0]B_^^_WJWO+
M,9-:]$6/+KE[MU[I/[L_X]7<W_AOYG_W75/NR?&GVCI->_[AW?\`S2;_`(Z>
MOE_M1TF0^<D./R-+!7XZN^4^*HZ^@JHUEI:VCJ=Y4,5125,3>F2"HB8JZGAE
M-O8_0TM)B#Z_\=ZY<W$<<O/D,<J!HVNT!!R"#<`$'[14=?1H^6&Q-N[G^&/<
MVPY\10)MVKZ7SF+I\5%31I14=/!@BM'%20!2L"T?C7QZ?T:1;V![1V6\@D+?
MCX_GQZZ.<X;?;77(N]V#1*+8V#*%I32`F*#RIY>G7S\?Y7-=4[;_`)CWQ2:B
MD*O1=V-BE-_2U+"F;HO')^'3Q+;GV-[\ZMOFK\)0_;0>O7/;VP#6GNARX(C0
MI>(?VBA_;4]?2[FIX:ZEDIJJ-9Z>KIW@J(G%TEBGB*2HR_E71R"/\?<:WME:
M;E9W5A>0K)9S1M&Z'@R.I5E(]"I(ZZ>H[(5=<,""#Z=5A=Y?$/-X&MR&Z.M(
M3EL%-(U54;;#?Y?CR]RZX];,U3!J'""Q4>^%WWJO[NKF3EW<-TYV]DK3ZWE=
MR9)+`?[D6Y-21"HJ9DKP4#4H]>`DS8^;H)52WW(Z9Z4U^1^9]/\``>BF;1WS
MO?K'--6;:R-?@,E2S?Y9BJA9!3.XX>*OQKE4D/%O5[Y\^WWNK[J>P_-!O^5=
MYNMLW:"2DL#AQ&[#!2>!J*X'`JPJ.&.A7=V-EN<#K-&LBD8.*CY@CUZMB^/G
MR'Q?<-#+B\A%'B]YXN!'R&/!_8KH=*AZ^A-@#$9/U*/TD^_H$^Z%]\+8_O&[
M0^S;O#'9>XUG$&G@![)D``::&H%!JXIQ6OIU%>_\OR;0ZS1U-FYP3Q'R/1B,
MO_Q:<I_VKJW_`-QI?>8G,?\`RKV^_P#/%/\`]6FZ#\/]K%_IA_AZH=PO_,T\
M9_CO^@M_B?XI!P?\/?R?[#_T_KE[_P`6>V_[34ZG.4G]URXK^@:?[SU>+O?:
M&+W_`+,W+LC.1F3$;JP-?@LC&/S2Y*F>GF`_PTO[^MBW9D2%U/<`/\'6/NXV
M,.Y65Y87`_1F1D8?)A0]?-2Z:S&3^'7\QO9==D(Y*&IZA^1M9!4Q,"&7%U>>
MRM!1"1?3>.2AKT;G\'W(,H6ZLBL9KJ7/YBO^'KF3M4\G)_N5;WEQ%H:TOL#C
M32P2H^U37[#UL`?\*;.ZH:K9GQFZ;HYU$F4R>2['RJQDDU.*GPCX^B+'58PK
M4JS"WU/Y]DO+T0#S2MPX?Y>L@OO/[VLECRWM$<E),SFGF&`1?YUZ,M_PFNZ-
M39_Q3WSW764[09?M;L#+8F,MP\V#VG,@QTZK8:8I6KWMSS;VGWV5FN$B;R!/
M[?\`8Z%7W9]BBL^5+W>Q&5GN9O#-?,1`"OV5)IZ\>BB_\*B_^/A^)W_:MWW_
M`.YV)]K.7/AN/M7_`"]`?[UO^Y'*G_-&?_"O1JO^$R?_`&2=W1_7_2_2?^\Q
M2>T>_P#^Y$/^D_R]"_[KM/ZK<PU&/K1_U;'1)O\`A3UEZU^T?CA@VE/\/@P6
M6RT4/U`JY7JZ9Y/]C$@'M7R^@H[_`-*G0+^]+/(;_:+;56/Z<M^9:G1]/^$U
M&R,+BOAKO??L%%3IG]T=L[IQ>2R"JHJ:FAP;T_\`#Z>5[!FBIONGT`_35[1[
M\7^J5#A:$C]IZD'[L]E;IR9=[@D8$\EQH9J9(5$I7UR3^WJD?_A1!A<-AOY@
M^1?$8N@QCY/KG9U?DC0TT5,:^LDQ09ZJI\2J)9Y&8DL;DD\^SC86;Z-0?XCU
M`OWD(((O<*Y,,*H6MX22!2I*BI/S^?6T?_)!_P"W9OQOMQ_N&S]O\/\`?R93
MV'-W_P!SI?L'^#K*WV+_`.G9<O\`_-W_`*N-T5/Y+_\`"?WISY.]_P#9_?N\
M.YM]T6;[0W4VY,AB:*%114$3QTD+XRC;[I"*;Q4ND<>D-P/;\.[M#"D/@Y50
M*U(X=!KF+V!VKF/?]TWZZWB0374YD9="G34`4!XT%,$\/+RZ.IV-W%\$?@=\
M;*?X\[^[#V#@MM;=V'-LO^XD<N+K=SYR(XN2CJ*BLVU2/]U55]?^N6250SOR
M2>/:9([R[N&N4C-2U21P%?GT,-RWGD+D/EA>6MQW*W2WCMS'X0TF1^VA)09+
M'B2?/K0#ZBK\6/E]UYE=GEZ3`S_(JER.T[1FFEI,%/N&JFPNF"Y-.T5"R#Q_
MV/I[&4RN+15:E?3_`&OKUS\V&>U?G:.;;R5MO'JF*$+XP*X\L4QU]1_;SO)@
M,')(Q>1\/C'=S]6=J*!F8_XL3?W'[?$WV]=3[4UMK<GB8U_P#K__U=_CW[KW
M7%OZ_P!/?NO?+RZ2^\]Y[8Z\VIG]\;US=#MO:6U<55YK<.=R<H@H,7C*.,RU
M-742D'3'&O\`@22;#GW94:1E5!5SPZ27U]:[;:7%_?3K%90J6=VX*HXD_+K7
M_P#A[\K/E5_,R^878/8>QY9]D?R[NOZ7)=>I05M+)1U_:61%5).F8H,E%HK8
MZIS$K1RP%52`@%@3;V6<^<C\M<Z\G[MR9S/'-)MM]"5;P9I+>56/!TEC*NNF
MF,Y/RXPER%SKSCSCSW-ONTL(.4[-RFEU5ED7B`<&KM\501I6BGNJ!8EOKX/Y
M2OJY*K:N^:JNB<NT-+NEY*F2E4DE((ZP^>=T4\`FQ]\>_=?^Z\WW=MPEW'D;
MW0FNV).A-S9V:->(02@NS`<*D#YYZRYLN=8XUTW-@H']#'\L=%T[,Z$[;ZQV
MK+E=U9B&MVO#54M*::FS-;64XGJ)"E*WVDS"%`LGT-KCWAA[[_=-^\%[(<@S
M;]SWS!'<\EQW$,7AQ7LLL>N1J1GP'`04.>%1Q'0BVS?=IW&ZT6\6F<J>*@?S
M&?MZ+FQ"@7&JQ%OZ7)_V]K^\(Z4Q7H2"BY!X4X?[/1Q<9\1>ZMU4F.J<KN.@
M7&U5+2U-.F1S-?6"*GGACEA"TCB:-2D3`6`XM[Z9;)_=Y?>=Y]VO9[W>^;;-
M=DG@BEC^IOIYBL;HK(!&5;31"``#0</+H&S\U[-:R2+%`QG!(-%`\^C(]7?#
M['[1JJ/)[GWAG<O+2S)4)A,;6U.,P_W$;!TED^SG@EJ+,HN&%B!S[S8]B?[N
MC:/;R\L-XYT]P-TO7AD63Z*VFEM[3Q%(*LS12([T(':0`?.O0<W/FR2[1DMK
M9!J%"Q`+4]!7`Z.NBJJ*J_I50%YOP!8<GD_3WTSCC$4:1K\*BF<\/GT#CQ/7
M+W?K77O?NO=)_=G_`!ZNYO\`PW\S_P"ZZI]V3XT^T=)KW_<.[_YI-_QT]?,(
MI?\`LNZ@_P#%KL'_`.]KC_\`>?8]'^XDWY_\=ZY=R'_D?V__`#VI_P!I(Z^D
MC\B)%C^,G:\DC!43JG/,S-QI7^!R<D_0`#Z^P1;BMS$H'XAUTHYF('*F[DC'
MT;?\<Z^=I_+:*O\`S&_C$R\)_I^J2#:]P:K.FXO_`%]C2]_Y)K$\"&!^7'KG
M5[=5'NGL-1DWD?7TH=U[XVGL/%P93=V<H,'03'PP3UTC1K/,L7D,46E6+2:1
M>UO<!^X7NE[?^U&U0[Y[@\T6VU[;*Y2-YF($C@:M"``DM3RZZA6EG=WK^':0
MEV`R!Q'2'Z_[ZZ\[,W!D=N;3R,M=6XZF6J>5HM%-/$;W^VD+:I3&!ZO3Q[BK
MVE^];[0^]?-VZ\F\B;M+/N=K")=3)HCE3-?":M7*4[L"G2^_V._VV".>Y0!&
M-/L^WH._DAT1M3?6TLQN>DHX<3NW!T$V1I,C1Q10BO6F#2R4F010B2K./]V&
M["W^/N'?OI_=4Y`]T_;[F?G>QVR.P]P=LM))X[B)53QQ&"S13J**VORD-74C
MYGHRY<WNZL[R"VDD+VKM0@^5<`C[/3AU61TUGZ[;':FRLM22-'+'G8:.JC1F
M"5$3F2":G<+;R0LQO8\7'OAO]V7FO=>0/?KV[W>QE=98=T1)%#$+(CDHR.`>
MY<\#BH!ZDK>8$N]JNT:C50T)\OL].KS\DQ?#U[G@MC*MB/\`%J1R?][]_5%O
MC>)RUO+G\5C*?VQ-U",6)HQ_2'^'JB#"F_:N,_PW_0_^[2#W\HFQ`#W\Y>'E
M_6>V_P"TU.IQG/\`NK<C_?)_XZ>K\5_0O]=(_P!Z]_6K%_91_P"E'^#J"3Q)
MZ^?%_/DZ7J^G_P"8=N;=U-1/C\7V[18'L7$O'&(H6FPU1C<?D)(#'8>JLI7/
MXY/L;;3)XUDL8^)?\AK_`)>N>/OQLS;![B7.Y2"EM=,)5'R*:6(^6I?V]%K_
M`)C7RN'S2[.Z2SF',E3)M7I79G4[1`R'R;C&2DI9'"OSY9VJTU$`DG\^UEK:
M-:+.`>TL3^V@_ET%?<#F]>?-RY?E@S<0VD45/4QZR?VDCK?F_E\=/Q=%?#3X
M^];_`&7V&1Q'7>WZC/1%%C=L_7T451E))54#]QIVTGZDZ?8*OY?&NYVKC4:?
M8.N@/MSM`V/DKE[;VCTSBV5G\N]@"Q_;UKF_\*B_^/A^)W_:MWW_`.YV)]B#
MESX;C[5_R]8T_>M_W(Y4_P":,_\`A7HU?_"9+_LD[N?\_P#&8*3C_P`EBD]H
M]_\`]R(?])_EZ%_W7?\`E5N8?^>U?^K8Z(C_`,*>>>ZOCN!_SR&3'_JY7?G_
M`%O:WE_^S?\`TW^3H!_>DTC>-H]?I/\`G_JSO_A-TRM\`<BH925[J[`+(+76
M\F/L3^>;>R_?V'U:GT6G\SU*GW:01[?R5I3ZQ_\`CB=43?\`"C+G^80W_B+=
MF?\`NH3V<;%_N(O^F/6/_P!Y2O\`K@7)KV_30?\`'17K9\_DA$#^69\;RQ`"
MX;/DDFP`&X\H223]`/8?W?\`W/F_+_!UE1[%T_ULM@/E67_JXW5-?\Y/^=)V
M3M[LK=WQ'^*&63;$>U*F;;G9W:%%&:K.U>?EA2*7:^TV77!!'&*E/\JA<3-(
M;"UO9EMFU*T0NK@\>'H/M^9].H<]Z/>O<;7<;OE+E9RGAG1+*OQLWX@AH0$7
M^-:DFHZ+Y\*?Y#O:GR=VHGR*^9O86Z]K[=S^'J=R8+;-3/)N/L'/4WA%525V
M>J]P2U,F(I*V&[1I'+Y"I^@X]NW>Z0P2>';1@M7\J_Y_LZ(>1_8S>>9;'^L7
M-VYS00R1:T`):9P,C46([2.%:M]G5)/6V%H=M?,;9>V<67_A.V/D>-N8HR\S
M?P[#;FK,?1&<\_NFG@75_C[.)'::S5RNEJY_WFO4#[-:Q6/.WTL1)C2Y*BO&
M@GH/Y`5Z^HOMO_CW<!_VI<5_[@P>X_?XV^T]=3[3_<6V_P"::_X!U__6W^/?
MNO=<6'TM_OK\?[;WO'GUZE017K5O_F%]X=@_S//EE@OY8/Q;S]91=2;7KZ7.
M?*3M+"SM]A#2XNH+5VWJ>MI@G./4F&6FE?\`RB4^E6`/L[M(ELX3=S#O\O7/
M`#[?7R'6,//N^WON5S1;>W?+<K#:HWK<2K\)*$!C_I8ZD:6%';R(!'6Q=T%T
M5UU\;>I=E=,]68"AV[LW9&&I,50TE#`(?NIX85%9DZLW=YJW(U6J:5F9CJ>P
M-@`"B:9YY&D<]Q_P>G60VP;'8<M[3:;1MT06WB6GS8_B8^I8U)_S=##8J.3_
M`%^G_&_;)%2*8Z.!7AY=%,^:(_XPK5@_7^/8/C\'_*C<_P!./?/3^\UQ]V3<
M<G_DKV/_`%=/0LY,'^[I-(_T-_\`!U404DE/[=BJ,#([,L<448(N\TKZ8XHP
M/JS$`>_G*+!*:OB\AQ)/H`,D_(=2XH+24`^T^0'J3P`ZNUZ^[:V[NEL-M+9$
MR;LEPN&Q$&X\UC7\N"PTXH*?_)6R/%-D*D@7M322A?H2#Q[^Q;V]MY(O;SD2
M21675M%G0'!_W&BX@Y'V$=8SS;S:7F[7UG8,)S'*P=ERBG4<:N!/^E)Z'4"]
MC_A_OO\`'Z^Q3I`I3]O1AP/SIUS]VZ]U[W[KW7O?NO=)_=G_`!ZNYO\`PW\S
M_P"ZZI]V3XT^T=)KW_<.[_YI-_QT]?+:WON.KV;\KMV[SQ]!_%:_9W?E1NJB
MQ6EW_BE5@=P09&#'A(@9'-7+`$LH)-^/<@Q)XEM(OS/_`!WKE;NMZVW\XM>(
M@9X[D,`?,K,6`_,BG6TA\@_^%"'QW[,^&^_=E[3VAO3#=\;TV/7;%EV9DH:6
MECVOF<C0#'U^9J9]1+8NDF+LD=EFTV!%P?8?MMHECOHV:1=`.K\O2G657-7W
M@=DO^1MQM8=NN(]YN(##0TTJQ&DN&K0J#D`9ZI!_DK]4;@[7_F,=$U.-HI<C
M1=:Y^7LO=\Z0R2PTM!3PY"&62HDC&B'775:VU$7!]F^ZRQPV,L)-'*XI\^H'
M]DMFO=[]Q=AO8D+103^*_KX:+\7[2N?7KZ`?R`ZR7M+KC+X*G5/XO1QMD,)(
MX+::RF34T0`Y+5,*F,6_)'O";[W'LB/?3V:W_ENRC3^LMJIN;)V!-)HQ5E`'
MG*@,8^9'#KJ%L&Y#;=QBF8GP3AA\C_FZI[V5O#<_4>]J;.8^!\=GL)--1U^,
MJT>$31/:.LH:J.P9E=!8$7^MP??SB>VGN'SY]W/W/L^9]KMI+7F;;97BG@F!
M74A[98)%K4!Q@TSP(\CU+UW:VN[V3V\A#0.*J1Y$<,_+HU'8_P`T,CN_9M=M
MK![8DP==F*1Z+*9"JJ$E2""9=-0,>(V+AV7])>YM]?>>OO/_`'F>Y>X?MKNW
M)7*_))VS=-RMC!<7#R!PB.*2"`!J@G@"^1T%]LY+6VO$N+BXUHAJ!PR.%>@:
M^-/7>1W[VE@)H::27#;;K8\QG*YE;P>.,/:G68CQM42RL#IN3[QN^Y#[/;][
MJ^^G*MY#8LW+FU7*W5[*0V@(G!=9[?$9BM%)J14T/1MS)N,5GM<X9@)9%HH\
MZ\*D>G5SV5L,1DE`X7&UJC_#32R`#_;#W]+>_H$Y<WQ%X"RF_E$PZAZ*OC1G
M^D/\/5#^%(/:N,%Q<;_H1_ZU(??RA;%7_7\Y>)_Z:>V_[34ZG*<?[JW`_P!\
MG_CIZOP4C2H_.D?[U[^M2+^RC_TH_P`'4%$9/IUJP_\`"G/I-,GU=T9\A:6'
MR5NS]SOUWDY5CN:;"9P5N;6666UEA-;36YX!_P!?V)^7YB'DAK08;]E`>L3O
MO1;`MQMFR;^L>J5&:WP"2`X9Q^6H4ZUFO@-TW+\@_F7\?>JZ>,5$.9WYC,QD
M$4:T6AVS/!N"9Y0O"PLE`02>+'V(MPF,-M+(.`4G_(.L6?;;87Y@YOV3;@"&
M>X3UX+5V!_):'Y'KZ@$,4-/%'!3Q)#!`B1111*J1QQQ@!(T1;!50#@#CW'))
M+?/UZZK!0H``HH'6H-_PJ+(_O!\3B65?]QN_/U$#_E.Q(_/U]BOESA<_:O\`
MEZPR^];_`+D\I@<?!G_PKT:G_A,D5/Q.[HY!MV_27L0;?[]BDM]"?K[1[^?U
MX2#^#_+T+_NNT'*W,)K_`,31_P!6QT`7_"GGJ3+R8'X\=XTE'+4X?%9K,;/W
M!5002RIBX)*"6NHJBNE4-'3T]14S&-6:P+\>W]@D76\18"AKGS'1)]Z+99YK
M;8]TBA9@VJ(E03IIW"OH#D#Y]$V_DR?S9^G/@WUKV)T]W[3YJDVU7Y^KWGM#
M.86"&LBEK\HX.4QM9')-&T#>.)/$R@J2+&WU"C==M>X8.CJ,GCCB:\>@5['>
M[VU\I;??;)NT$IMZAHR@J=0`5JCY@"E*]5Y?S1_EJOS>^2=3\@\3L#/;`V#F
M,#2;;V$-QQ".OW'C]L1C'5>865`*::&5RC#QDA0W)]F.V6PMH%C\0$U_P_;U
M&WN[S6W.G,\F_0[=)!9RHJ('R2L?;JJ,5)\O+@<];FO\EA9)?Y7'0*0^J63:
MV[$AT&Y:1LWF%321^=?^\^PKNO\`R4)/R_P#K-7V1!/M;LJK\6F8?GXC]:'_
M`'3-G>O?E_V36[SQM15[@V7WRV=W%A\FK_=5K8;<E'F):6H6J]3&IHH%12_I
M]0OQ[%\`62V/A&O#_`.L!N86N-IYPGGW16,L-RQ8'B:2$T-?7SKY=;8G:7_"
MCSXSP=()3=/]?;MW!W#G]M_PG&[!^SHX:#;.7JZ1Z41UWVKAJNBH9&4A*6-B
MPX`'Y#2[-,+DI+*--:XXGK,'<_O$[#_5Y3M&T3MN4L5%0@".-B*9-0"!Y!>/
M#K4HZ;S%?N+Y4]8;BS*14V9W)WQC-P9:F16A2ERN8S<]=7TJ0RD30K!4S,JH
M_J4"S<^Q-<(BVR)7'_0IZP^Y<N9[[G&&ZFCI*\]3B@J903C-!4GS/V]?4MVW
M_P`>[@?^U+B__<&#W'KX9OMZZIVO^XMM_P`TU_P#K__7W^/?NO=55?S@?FK4
M_"_XC[CSFTI/-VWV?.W6_5V,A]60GS.>B^QK<EC4%V>KPM/5K*FE68.5(%_9
MAMUJ+FX`;X%R?GZ#\^'46^[G.+<H\K2FU8?O6\)AA&=611W6F2T:G4``36E!
MTF?Y.7P5B^'OQIHMR[T1<MWSWLU+V3VENFJ=ZC(SU&?IDR>.Q4LDZ>6":B@K
M3]P`?7,22+CWO<KDSS>$I_23'YC!/\L>@Z3>T/)(Y5Y>6]O*-O%]^K(V:A&[
MD3.:@-5_XF))SU;W[+NI;ZXM_L??OEUX\".B!?S&^X>K>G/CW7Y[L[>F)VK1
M'-X=J&BJ*FGDSV<GCJN*';N#-1#D,U7/^(J=7?\`P]X3??W]NN=_=+V+')W(
M&P2[ES)<[Q9:(DQ@2]SNU"%51EF:@'GTIL^<.6>39GW;F;=H[6P2)N--;&F%
M1*AF)\@*UZI@V7M'M?Y#XZB[&[3HMP_'3XN22I4;=VB9),5WEWQH(>`21F"+
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M[]U[I/[L_P"/5W-_X;^9_P#==4^[)\:?:.DU[_N'=_\`-)O^.GKYA-(P7YWT
M!9$D4_*["*\<BZHY4.]<?JCD4\-&XX(_(]CY32TE/V_\=ZY=R!3S_;:EU+];
M'C_J)'6[/\I?Y&?PQ^5&X(.R(L1G.I-Z9."CFS4_7%:F$PF:=U\M14U^'CIW
M1JZ9I"6E#7)/(]A6#=KJ#5&SEE^T@_M'6</,_L9R7S1.NXBV-I>,HU>&%T$G
M))4@C4?,CHVGP=_EQ?&_X"[>R^.Z:P>1JMR[F$(W1OO=-6F5W1E8X54+1KD/
M!"U-C%=`P@6X+C43>WM)=WTUZ:R'M'^KSST+N2/;CEOD*"5-G@9KJ04>5Z%B
M/X1I"A5KG2!2O1^#P/\`8W%_][O]!Q[1DBM3PZ']?V=`3V5\<^L^T*ELEFL7
M+0YEQZ\OAY%HJN>P(7[HA'$^F_!X/O%/WK^YM[)>^5[+O7,VQ/:<SL.Z\M&$
M4LE.'C=K"0#YBOSZ/-LYAW':U6*&0-`/PL*@?9Z=!!C_`(-]905*2U^6W)70
M(X<4XR`BU!?[#-XFN#^?>.VS_P!UQ['VEY'/NN][M<VZM70)4CU#T)$9/[*=
M&LG.FY,I"1H#7C0G^5?V=&HV;L;:VP<0N$VGB*;$T"E7D6G15EJ9571YJF4#
M5/,1]6/O/;VX]K^1?:;8$Y8Y!Y>@V_:Q0L$`#2,!37*P%7>GXC^708O+VYW"
MX:>\D+R'S/E\@/(=*FHA2JIYZ>35XZB&6![<-HE1HWM^0=+<>QM=V\5[9W5G
M-7P9HV1J<=+*5-/R..DH+*P9>(Z*[2_#_J*ESD.X8EW)_$(,K%F$U9B\1JX9
MEJ$_;^W_`,UY%%UOR/>"=I_=U?=\M>:++F^%MZ_>L%ZETO\`C?9XB2"4`KX?
MPZ@*BM:8K3H4'FW=3`8"(]!73\/D13UZ-,```!P!P/\`D?O/110*%X`=!<^O
M1<?E1\6>I_F+U!G.DNY:'*UFSL\\,\SX3(?PK+T=53M>&JQ]?X:C[>=`2+Z3
MP2/:F&>2W<O'2I%,]!OF?EC:N;=J;:=W60VK,#V&C!AP()!'\NB7_%3^33\-
MOAUV[C^[>IJ'L*;?.)QM3C,;-NG=QS6/HX:R*2GJ98*,X^GTU$L$K*6U?3VK
MN-VNKE&BE(T$4P*<.@1RG[+\F<F[K%O.TK<M>QZM/B2!@-0HQII'E\^K7OH;
M6X/^P_VP^I/LLT_LIU+6:$]5_P#S:_EK_''Y^5>Q*SOA-[--UU!E(-O':6Y3
M@%T9B6GFJ_O`*.J^X(>F73^FPO[76=_/8^)X0%&IQ^74><\>V7+?N!+82[]X
M^NW5E3PWTX>A-<&O`>G2Y^%_P9Z0^!VQ-Q==]&KND;?W3N"/<N4_O7G#GJXY
M*.B2@4PU!IJ8Q0>",>G2>>?;5U=R73(TP%1C`ITNY)Y#V/D.QN]OV/Q3!/+K
M;Q&U'4!3&!04'0U]Y]&=8?(WK+<O47;^V:3=>QMU4K4N2Q=4`'5K$P5E'/I+
M4M;226>*0"ZN`>?;<$LL$BR(PU#H^W[8=KYEVRXV?=[82V4HR.!!'`@^1!R"
M//JD':O_``FW^$&"WTNX<OGNU=R[4IJH55+LO([LO1S*C!DH\G4"BUUE$;6=
M`%UJ2+CV:OOMR4.H#(XY_P`'#J#[;[MW)$5\L\LL[VRM4)50<<`7"ZC\^%?/
MHY/R6_DY_"[Y2/UO%O7;FZ]K8GJC;E3M;9NW^NMP)M3"4&*JG@>=9:**@J1/
M42M3H3(2&-N;^TUONEW;EB&5F)K4C_9Z&/,GLWR7S0NWI=V\T,-M'X:)"X10
MM0>&DYJ!GCT=GXT_'7KSXH],;.Z(ZL&:&QMCP5=-A/[P9'^+9;16UD]?-]U7
M>&#SDSU#6]`L./:6>=YY'F<#4?3H;\K\N;?RGLMKL6U%S90ZJ:SJ;N8L230>
M9/EU7K\U/Y*OQ)^9V_:OMG/0;GZ][-RIU;AW#L?*C&4NYYM*+][G<?X)%J\E
MIC4><,"0H!'Y]K+3=;FVC$88,@^T?X#U'O.GLGR?SCN$F[3Q/!N3FKLFFDA_
MB964]WS%#UB^)W\D+X3_`!7W)2[[I=MYGM+?5$)?L<OV17P[@H,6\I0^?%XF
M:E2&FJDT#3(68@^]W&[7<Z^&7HG\_P">>J<J>QW)/*UPM\MJUS>#AXNDHOH5
M0*`"/7CTDI?Y`_P.?M"?MN&/MNCW7+OJK[#C6FW\T>-I-P5F2GRKBFH_X6?'
M0QU50VB+4=*V%^/>QO%T8DBHI"\,9].DO^L%R*-SEW96O!>/*7/ZHTU9M9`&
MGAJX9P,<.KK*"CBQU!18^%G:&AI*:CB:5M<K14L*01M(]AJ<H@N?R?9834DG
MB>IKBC6*..)?A50!]@%.O__0W\II8X(99YG"0PQ/-+(QTA(XU+NY/^I502?>
MJ'X%X]:+*JLS8`S^75)/\Q/XI[V^5OR?_E]=CX+'3;UZ-ZO["W'G]^TU"%F&
M+K8TPTVW<E)36/W-#5UU(1*UQI1/Z>S:RG2WBND8TE(X4SP('^'J$O<+E:]Y
MKYDY%W&VB:;98)V,FG\-&1@2/,,5%?D.KME"HHC151(P$1%4*BH@L%4``*J@
M6`'T]E-34X[L_GU-N%`6E.DGOKL#9?66V\CO#L'=.#V;MC%Q-/7YW<.1IL9C
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M-0?(=#/NCICY&;VR\^<W/MK*Y+(2`K$7UK!0P`WCI,;3^I**CA'"1)90H``X
M]\'.?ONU_?$]S>9=PYMYTY,W6^WRY<LS25-*FNE%X(@_"HH`.'66=IO'+]E!
M'!:W*1VZBFD8I]G1S^I-Y_),9S:VV-Z["@I=LP"&@R&=T+!+#1TU,T<,GC4$
M:@(D!YY)]]+_`+OGN1]]!.9.0>2/<?VL2+DN/1;W-X8Q&T<$<95'H*U8:44Y
MS6O0.W2SY<,%[=VMZ3<GN5:^9/1T+$WMQ;_>_P`G_;>^EQ\ZXZ!WI]G7/WL<
M!U[KWO?7NO>_=>Z9-R4T]9M[/TE,GDJ:K"Y2FIX_IY)YZ&>*)+_[5(P'ORD!
MP3P!'2>[1GM;E$%7,;`#YD&G6@C3_P`J'^8`GR\HNP'Z$R0VE%\BL1N^3+?=
M'Q+MZGW119"7(V\7,:TL;-;_``]C#]Y6PMF0.NHU_P".TZP(?VDYU/-MMN)V
M:?P/J48D`4`$P<FOI3^?6_WCT>*@H8Y!IDCHZ:-Q_J72%%=?]@P]@\@$X/GU
MGW$&6*)2,Z0/Y=31R.??OMZN.'7?OW6^O>_=>Z][]U[KUO?OGY]>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO6'OW7NO>_=>Z]8>_<>/7NO>_=>Z];WZ@I2F.O=
M>]^Z]U[W[KW7K#WX8X=>Z][]U[KWOW7NO>_=>Z__T=]O<V,FS.V]PX>FD$-1
MEL'EL;3RW*B*:OH)Z6*4L""-$DH/'TM[LK`.I/D1TGNXVN+6Y@4]SQLH^T@C
MK3LZ\_FU_+[^6IV!V/\`&'Y)]$[A[.VOM;>^X)MD;G^SSPW!)MFKJ0^)3&3T
MT51C,CA&@6\+-)Y`/K[$DFWP7RB>)B"?3-?6H`QUA_MONGS5[:7MWRMOFUFY
MMXI6TO(2C`5-`C,0KH0`01P!H<]#1-_.J_F*?*>2?:/PQ^#>5AGK088]X9ZD
MS?W>*+<_<F'(_:XDQQ(026+#VPVV6<`U33FI]<?GZ]'?^O-[A<T&6TY2Y0[O
MXU#.P)X$$D1TIQ-3TJ=B?R;_`)I_,K<-!V/_`#-OE#N6IPTC0UB=/[%KYJ>B
M:G:05$F&SM)$U-AH(@0(RT222`+P?=7W"VMQIM8P3]E!_A)/^#Y=+=O]H><>
M;;F/<?<'F.81&A\)6#,?,J0%6-/2J@L/)NMA7XZ?%'H+XI;*H]A=$];;>V+A
M:2)$EJ,?11-E\E(H`>?)YB57R%;+(P+$/(5!)L![*);B2<@R-CR'`#[`.I_Y
M>Y6V+E>U6UV;;TC4<6/<['U9VJQ_,_ET8@@\6/\`K_7G_C?MD5S7H0'R(Z[L
M;?\`(_K[U3)KPZWUT`?R;C^G^^^OOP&,FO7C_+KUC_O%O]]?WORIU[U`ZY>_
M=>Z][]U[KWOW7NN)'OWD0>O?X.O6/]>/]C[\.`KQZ\>/#'76D_X?[S?WX4&!
MUZI]<=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7__TM_8_I_'X^O^P]Z'$=;\^B^]M6^_HK_Z`/J?^9K:OXA]!_P#T\_Z
M_P"+>WXOA/Q\?+H.[M_:)_R3^'^C\?\`BNE_L3_@!3?\R[_S9_X\3_@!]!_P
M&M_8]U?B?B_/I?M_]FO^XW_-KX?RZ$,_G_8?T_WCVROQ'HR/EUV/S_KGW<]>
MZ[]ZZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0[L17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`V.C`S.C(R(#(R.C0P
M.C`T``````.@`0`#`````?__``"@`@`$`````0```*B@`P`$`````0```)4`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```-O@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`'(`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DDDE*223$I*4DHV6,K87O(:QNI<3`'S65D]=9.S%
M9O/^D?H/[+?SDZ,)3-1%H,@-RZTCMJDN8MSLR[5]SM>S3M'W-0'N<027.)\=
MQ4XY.=694QG..@MZ[Y*((.G@O*NNY&5C]?SC3D6U$7D@L>YL0&_NN5SIGUXZ
MWAN:,EPSZ1RVR&V?V;F_]_K4%.W_`*"YF6*.7%*&3CB)\'RSX9_WO2^ECF5)
M9'1?K+TWK(VXSBW(:)LQ[/:]H/?]VQG\NI:H<=-.4*<N<)XYF$XF$A^C(4R2
M3`R)X3H+5))))*?_T/54DDDE*0[;655NLL<&L;JXE36%UO)]2YN.QTMKUL`_
M?_\`,4_'CXYB/XHE*A;6S<^W,>=WMI'T*_+]Y_\`*58GB=?CX^2<22``2YQ@
M`:DE;O3.G"AGJW-'KNU\=@_=:KLIPPQJM](CNUQ$S.KFX_2LR\!VWTFGAS])
M_L?25K_F^2V'7P3R`W1;*8B?DJIYG*>M,HQ1'2WR7ZR$?M_.UXN<)XX`"S1Q
MJ0O6\KI?1AZN3D85#R`ZRVQU;7.,#<XRX>YWM6-T;,^I_7B^G&Z?6RQC/4-5
MU#&N+/H^HQS-[?SOZZC>GP?'!'!IR\Y0PPA"<Q+Y>#T\7ROG]=EE5C+JGNKM
MJ.ZM[##FG]YI7H_U3^M'[88[&RMM?4*1N=MT9:R8]:L?O?Z6M<E];NBT])ZF
MUN,W9B9+#94R2=K@?TS?=]%NYWL61C95^'DU9F,2VZAP>P@Q,?29_P!=;^C<
ME3<YGEL/Q+E(YH_/P\>.?Z4:_P`G)]G;,!257`S<?/PJ<RATU7M#V^7[S?[#
MO8K(37D2#$F,A4HFI#L5TDDDD/\`_]'U5,G3%)2.^X4U/M/#&EWW!<JYSWN-
MCS+G'<?B5T'67;>G6D=]H_$+G^/[E<Y2-1,O&F',>CI=$Q?4M.2X>VK1GFX]
MUN0J?2JQ5@5"-7#>8\U9]1N_8""X07-&I`,[7.'YN[8Y5\TN+)(]C0^C)`5$
M)$Q3256/4<7]H-Z9O!S74NR15!_FFN;2ZPNC8W]*_9M4:Y)E"MV/8V[2LL=Z
MA'(;#MW_`$5S7U3Q_JE5D/LZ)D.R,@U@$6N.X5RT^QKVU[N%OY-E-[K>G[P+
MWTEX9^<&.FH6Q^[O7*?5KHN#T;KXQKL]N3U%E)8W'KJ>&@O:+/TF0=]3+/2J
M=;7C/L]7TOTR+:P3Q?=^8$\T\<R!P8H_+F/:3F_7C"ZI5U)F5F6-NQK0:\5U
M8V-8`=[J/3W.]_Y_J_X1<XNY^O)ZAF^ETW#PLB\4O%UUS*G&N=NUE5;X][O=
MO?M7)_L3K/\`W`R1_P!:</RA'7H'I?A'-0^Y8QEGCQR&@CQ1Q^G]&1B7K/\`
M%UGFS$RNG./]'<+:S/YMD[Q_9L9_TUV(G=]Z\_\`J3@]5P^N%V1B74T6T/8^
MRQA:V06/9[G+T$<H'1Y_XO'&.=R''*,HY*G<#Q#B_29)))(-!__2]53%.F*2
MFAUL3TZSR+3_`-(+`[KI\VDW8MM0Y<T@?$:A<N)@=SW^*N<H;B8]I,&8:@M[
MJW3<OJWU?Q\;$>R=U9MIL<]E=S&;A9BWWXVZ^EC_`.<_1M_P7I/_`)Q<[B?5
M'KMG5!6,NRG(Z91BXXZP_P!0V2UN1DV4]/JAE&7A;\NG&N^VV7>RBSV>K_-]
M9T#)'IOQCRTES/,'E:XA5LL>')(>/YLT38#P+_J#U:WIC,5V4&75UW01DY#F
M'*L^QM;G;ME-O_:;*R?0=ZM=67<S^>_2K4Z]]6>J=1Z[3U/"LII=170VG(L?
M:+:W4VVY-S&T4C[/D5YVZBBUV19^BJ9;Z=-GJ+JDZ8E\_/\`B_ZLVCT:\L.J
M=3BLR:#D9#1?94V_[7:_)+;K<?\`6K:LC&92STG^AZ=M+$V)]4^IY>1U*VIU
MN$+<VS&R++W7-MOQF#!I^TU_29;ZU-/4GUW[?Y[)_1V,K7H*8E)-E\U'1\W&
M^M&'T[(IS;\"J\64>@^YU=8LORLQGZ6]K:'8E%#\6GJ>^W[2^STO2]5=%GG=
MFWD&1O(!^"Z+)R&44OM<=&"8\_S5RTDR7?2)EWQ*M<K'4R/DP9R-`WNBMGJ`
M(G1CI_#E="%C]!J,77GAT,;\OI+8"BY@@Y370+\8J(M=)))1+W__T_54DDDE
M+%<[U3%^SY1<S^;N)<V.`1]-JZ)!RL:O)H-5G!X/<$?1<%)BR<$KZ=5LXV'F
M*K;*;6W5:6,,C_OS?[:Z3"S:<RO=68<![ZSRT^:YW(QKL:TU6C7\T]G#]YJ@
MQ[ZWBRMVQ[>'#E7,N*.8`Q(OH?\`OF&,S$Z[/7)UAT==N8T-OK%A_>:8,?U%
M9'7<0B7-L:?#;/XJG+#D'Z)^C,)Q/5TE%[VL:7N(:T:DG@++MZ_6!^AJ<X^+
MR&_]']U9V5FY.6?TSAL!TK;H)_[\G0Y:<]".$(EEB!O:7J>?]L?Z;#^KLX_E
M']Y4VL<][6,$O>8:/$E-X?<`/'P"W.E=../%]W\Z1`;^Z#_WY69RCAAPCZ,0
M!G*RW,3&;C8[*1J6CW'Q)^DCI)U0))-G<MA22222G__4]5232D3"2ETR8NY\
M4S7AT^1@_E_ZE)3#(QJ<BLUVM#FG[Q_5*QLCHN342ZD^LSD-F'_^1<MTG3XI
M:I\,LH;%;*`.X>2L#JSMM!K/@X0FD>/S75N]-QV.`<>=I@F"8^BY4NI6]%Z;
MBOS^H"JBBJ"^QS?'1H:QH<^Q[_S*V-WO5B/-]X_BQG!V+@[F\`@D]AJ59Q^F
MYF2?;7L;_I'R!'D%=P_K#]7LA^$S$N8ZSJ+K68C&UN#G.QQORF6-]-KL=]+/
MI,O]-;`\Q]Z$N;E^B*2,(&[2P>ETXL/=^ENYWG@?\6U7H3!WS[)YUA5I$R-R
M-L@`&RDZC*6[RE!+))1W\S`CG5.$E/\`_]7U#*-XQ[3C!IO#'>B'Z-+X_1[_
M`.1O7G5(^LIZ)98U_7#U!UV,WK0N!:YM)=;]N_YNU,_1^HW:S;9C?]I_37I*
M4)*?.\3I_P!:,YW3<&_(ZKB=.R,O/L;?ZKF9->&VNL8%.=<YCW,MMR76>DS)
MWV^G]#Z'Z.GT`=;R^NY.5TQ^2<H]6O=DYI#JNF6X=3/L[6V5-<ZJW*LO;LI]
M)EM_^%LL_/7J'=5.F=*PNE8C<+`J]#'8YSVUASG`.>XVV'=87/\`IN24^=>K
M];V861;C-ZR[,&%;7U1N5N@YEKF4XW[%KJ/M]"QUM_JX?Z'[!Z7^$1_K%T[Z
MP=,+\*G*Z[GT_8WWXMV,Y]CW9SR:O3RLBC8^O$QV,IMJQ=GO]2U>DI)*?+LC
MI7UDPNI=;MQ&=2LZB>GXC<+-#G/8]K6TMZH-]C_TF;_2'8>-_.,L]:VEE=GH
MI[L'+SK>C=/S<O.+LCJSGXS+?M.*]N/CU#(R+6-S+[\Q_P"E]-]&3=9ZU#_6
M^S^FO4#,*K=T[$OS,?.NJ:_*P]XQK3,UBT"N_9K_`(1C4E/G[!];LME.8S"R
M6]1Q<#J&11;DAVYEV7E^C7C5^J/Z1C]-I]7%Q_\`B?\`!+8^K&1UO&INK?\`
M;,O[:YS<(Y=%[&8]E5/JO?EVY]]^=]DR[7,:Q_\`W(]>NK]'L790DDI\UH'U
ME=T;(MGK9ZJZREO6/4!:6T.>]V;_`,W*V_JWKM]K:_1_P'\UZ:LXE'UAR#A8
ME[NJU=,MSLS)9<;'MRAA54M^RX^5>T^LS[5EV/\`1JR/UO\`T?\`I%Z"E"2G
MSGH&1]:.F.P,OJ-75LZ.G.LZA3#K=S[+VX^#CTT6FMM6;CT?K&4]S_7]#])8
MB9Y^L]_UH:+!U*H5]5H;4,?U&]/'3FQ8ZVVRGV79%_T<GUG?H]Z]"2A)3P70
M,GZS976.CTYM/4,=N+;U*WJ;[P\8]AL<YN!4RPNVVUT,>WT/\%_W'7>CA*$Z
M2G__UO54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22G_]G_[1.B4&AO=&]S:&]P(#,N,``X0DE-!"4`````
M`!``````````````````````.$))30/M```````0`$@````!``$`2`````$`
M`3A"24T$)@``````#@`````````````_@```.$))300-```````$````'CA"
M24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*````
M```!```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`!
M`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&````
M```!`#4````!`"T````&```````!.$))30/X``````!P``#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`
M``````0`````.$))300:``````-C````!@``````````````E0```*@````7
M`$\`<`!E`&X`(`!"`'(`:0!E`&8`:0!N`&<`(``M`"``50!P`&0`>``Q`'@`
M,0````$``````````````````````````0``````````````J````)4`````
M`````````````````0`````````````````````````0`````0```````&YU
M;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P
M(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```)4`````
M4F=H=&QO;F<```"H````!G-L:6-E<U9L3',````!3V)J8P````$```````5S
M;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG````
M``````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N97)A
M=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(`````9B;W5N
M9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,
M969T;&]N9P``````````0G1O;6QO;F<```"5`````%)G:'1L;VYG````J```
M``-U<FQ415A4`````0```````&YU;&Q415A4`````0```````$US9V5415A4
M`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA434QB
M;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU;0``
M``]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI9VYE;G5M
M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4>7!E
M96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U='-E
M=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/=71S
M971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$$0``````
M`0$`.$))3004```````$`````3A"24T$#``````-V@````$```"`````<@``
M`8```*L````-O@`8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B95]#
M30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5
M&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-
M"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`<@"``P$B``(1`0,1`?_=``0`"/_$
M`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`````
M`````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A
M$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C
M=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='
M5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R
M@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V
M=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'
MEZ>WQ__:``P#`0`"$0,1`#\`]522224I)),2DI22C98RMA>\AK&ZEQ,`?-96
M3UUD[,5F\_Z1^@_LM_.3HPE,U$6@R`W+K2.VJ2YBW.S+M7W.U[-.T?<U`>YQ
M!)<XGQW%3CDYU9E3&<XZ"WKODH@@Z>"\JZ[D96/U_.-.1;41>2"Q[FQ`;^ZY
M7.F?7CK>&YHR7#/I'+;(;9_9N;_W^M04[?\`H+F98HY<4H9..(GP?+/AG_>]
M+Z6.94ED=%^LO3>LC;C.+<AHFS'L]KV@]_W;&?RZEJAQTTY0IRYPGCF83B82
M'Z,A3)),#(GA.@M4DDDDI__0]522224I#MM956ZRQP:QNKB5-876\GU+FX['
M2VO6P#]__P`Q3\>/CF(_BB4J%M;-S[<QYW>VD?0K\OWG_P`I5B>)U^/CY)Q)
M(`!+G&`!J25N],Z<*&>K<T>N[7QV#]UJNRG##&JWTB.[7$3,ZN;C]*S+P';?
M2:>'/TG^Q])6O^;Y+8=?!/(#=%LIB)^2JGF<IZTRC%$=+?)?K(1^W\[7BYPG
MC@`+-'&I"];RNE]&'JY.1A4/(#K+;'5M<XP-SC+A[G>U8W1LSZG]>+Z<;I];
M+&,]0U74,:XL^CZC',WM_._KJ-Z?!\<$<&G+SE##"$)S$OEX/3Q?*^?UV656
M,NJ>ZNVH[JWL,.:?WFE>C_5/ZT?MACL;*VU]0I&YVW1EK)CUJQ^]_I:UR7UN
MZ+3TGJ;6XS=F)DL-E3))VN!_3-]WT6[G>Q9&-E7X>35F8Q+;J'!["#$Q])G_
M`%UOZ-R5-SF>6P_$N4CFC\_#QXY_I1K_`"<GV=LP%)5<#-Q\_"IS*'35>T/;
MY?O-_L.]BLA->1(,28R%2B:D.Q722220_P#_T?54R=,4E([[A34^T\,:7?<%
MRKG/>XV/,N<=Q^)70=9=MZ=:1WVC\0N?X_N5SE(U$R\:8<QZ.ET3%]2TY+A[
M:M&>;CW6Y"I]*K%6!4(U<-YCS5GU&[]@(+A!<T:D`SM<X?F[MCE7S2XLDCV-
M#Z,D!40D3%-)58]1Q?V@WIF\'-=2[)%4'^::YM+K"Z-C?TK]FU1KDF4*W8]C
M;M*RQWJ$<AL.W?\`17-?5/'^J560^SHF0[(R#6`1:X[A7+3[&O;7NX6_DV4W
MNMZ?O`O?27AGYP8Z:A;'[N]<I]6NBX/1NOC&NSVY/464EC<>NIX:"]HL_29!
MWU,L]*IUM>,^SU?2_3(MK!/%]WY@3S3QS('!BC\N8]I.;]>,+JE74F9698V[
M&M!KQ75C8U@!WNH]/<[W_G^K_A%SB[GZ\GJ&;Z73</"R+Q2\777,J<:YV[65
M5OCWN]V]^U<G^Q.L_P#<#)'_`%IP_*$=>@>E^$<U#[EC&6>/'(:"/%''Z?T9
M&)>L_P`76>;,3*Z<X_T=PMK,_FV3O']FQG_378B=WWKS_P"I.#U7#ZX79&)=
M31;0]C[+&%K9!8]GN<O01R@='G_B\<8YW(<<HRCDJ=P/$.+])DDDD@T'_]+U
M5,4Z8I*:'6Q/3K/(M/\`T@L#NNGS:3=BVU#ES2!\1J%RXF!W/?XJYRAN)CVD
MP9AJ"WNK=-R^K?5_'QL1[)W5FVFQSV5W,9N%F+??C;KZ6/\`YS]&W_!>D_\`
MG%SN)]4>NV=4%8R[*<CIE&+CCK#_`%#9+6Y&393T^J&49>%ORZ<:[[;9=[*+
M/9ZO\WUG0,D>F_&/+27,\P>5KB%6RQX<DAX_FS1-@/`O^H/5K>F,Q7909=77
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M>Z*V>H`B=&.G\.5T(6/T&HQ=>>'0QOR^DM@*+F"#E-=`OQBHBUTDDE$O?__3
M]522224L5SO5,7[/E%S/YNXES8X!'TVKHD'*QJ\F@U6<'@]P1]%P4F+)P2OI
MU6SC8>8JMLIM;=5I8PR/^_-_MKI,+-IS*]U9AP'OK/+3YKG<C&NQK35:-?S3
MV</WFJ#'OK>+*W;'MX<.5<RXHY@#$B^A_P"^88S,3KL]<G6'1UVYC0V^L6']
MYI@Q_45D==Q")<VQI\-L_BJ<L.0?HGZ,PG$]7247O:QI>XAK1J2>`LNWK]8'
MZ&ISCXO(;_T?W5G96;DY9_3.&P'2MN@G_OR=#EIST(X0B66(&]I>IY_VQ_IL
M/ZNSC^4?WE3:QSWM8P2]YAH\24WA]P`\?`+<Z5TXX\7W?SI$!O[H/_?E9G*.
M&'"/HQ`&<K+<Q,9N-CLI&I:/<?$GZ2.DG5`DDV=RV%))))*?_]3U5)-*1,)*
M73)B[GQ3->'3Y&#^7_J4E,,C&IR*S7:T.:?O']4K&R.BY-1+J3ZS.0V8?_Y%
MRW2=/BEJGPRRAL5LH`[AY*P.K.VT&L^#A":1X_-=6[TW'8X!QYVF"8)CZ+E2
MZE;T7IN*_/Z@*J**H+['-\=&AK&AS['O_,K8W>]6(\WWC^+&<'8N#N;P""3V
M&I5G'Z;F9)]M>QO^D?($>05W#^L/U>R'X3,2YCK.HNM9B,;6X.<['&_*98WT
MVNQWTL^DR_TUL#S'WH2YN7Z(I(P@;M+!Z73BP]WZ6[G>>!_Q;5>A,'?/LGG6
M%6D3(W(VR``;*3J,I;O*4$LDE'?S,".=4X24_P#_U?4,HWC'M.,&F\,=Z(?H
MTOC]'O\`Y&]>=4CZRGHEEC7]</4'78S>M"X%KFTEUOV[_F[4S]'ZC=K-MF-_
MVG]->DI0DI\[Q.G_`%HSG=-P;\CJN)T[(R\^QM_JN9DUX;:ZQ@4YUSF/<RVW
M)=9Z3,G?;Z?T/H?HZ?0!UO+Z[DY73'Y)RCU:]V3FD.JZ9;AU,^SM;94USJK<
MJR]NRGTF6W_X6RS\]>H=U4Z9TK"Z5B-PL"KT,=CG/;6'.<`Y[C;8=UA<_P"F
MY)3YUZOUO9A9%N,WK+LP85M?5&Y6Z#F6N93C?L6NH^WT+'6W^KA_H?L'I?X1
M'^L73OK!TPOPJ<KKN?3]C??BW8SGV/=G/)J]/*R*-CZ\3'8RFVK%V>_U+5Z2
MDDI\NR.E?63"ZEUNW$9U*SJ)Z?B-PLT.<]CVM;2WJ@WV/_29O](=AXW\XRSU
MK:65V>BGNP<O.MZ-T_-R\XNR.K.?C,M^TXKVX^/4,C(M8W,OOS'_`*7TWT9-
MUGK4/];[/Z:]0,PJMW3L2_,Q\ZZIK\K#WC&M,S6+0*[]FO\`A&-24^?L'UNR
MV4YC,+);U'%P.H9%%N2';F79>7Z->-7ZH_I&/TVGU<7'_P")_P`$MCZL9'6\
M:FZM_P!LR_MKG-PCET7L9CV54^J]^7;GWWYWV3+M<QK'_P#<CUZZOT>Q=E"2
M2GS6@?65W1LBV>MGJKK*6]8]0%I;0Y[W9O\`S<K;^K>NWVMK]'_`?S7IJSB4
M?6'(.%B7NZK5TRW.S,EEQL>W*&%52W[+CY5[3ZS/M678_P!&K(_6_P#1_P"D
M7H*4)*?.>@9'UHZ8[`R^HU=6SHZ<ZSJ%,.MW/LO;CX./31::VU9N/1^L93W/
M]?T/TEB)GGZSW_6AHL'4JA7U6AM0Q_4;T\=.;%CK;;*?9=D7_1R?6=^CWKT)
M*$E/!=`R?K-E=8Z/3FT]0QVXMO4K>IOO#QCV&QSFX%3+"[;;70Q[?0_P7_<=
M=Z.$H3I*?__6]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`.$))300&```````'``0`
M```!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K
M970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_
M/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*/'@Z>&%P;65T82!X
M;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T:STG6$U0('1O;VQK:70@
M,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F.E)$1B!X;6QN<SIR9&8]
M)VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G
M('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z83$R.68R,S0M8F$Q92TQ,61A
M+3DT93,M83@S-#0Q,68X,&(V)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W`Z83$R.68R,S(M8F$Q92TQ,61A+3DT93,M
M83@S-#0Q,68X,&(V/"]X87!-33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I
M<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N
M9#TG=R<_/O_N``Y!9&]B90!D``````'_VP"$``8$!`0%!`8%!08)!@4&"0L(
M!@8("PP*"@L*"@P0#`P,#`P,$`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P!!P<'#0P-&!`0&!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`)4`J`,!$0`"$0$#$0'_W0`$
M`!7_Q`&B````!P$!`0$!```````````$!0,"!@$`!P@)"@L!``("`P$!`0$!
M``````````$``@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S`0(#$00`!2$2
M,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*BLF-SPC5$)Y.C
MLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FY
MR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!``(1`P0A$C%!
M!5$382(&<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,7
M5),("0H8&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%E:6UQ=7E]496
M9G:&EJ:VQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)
MV>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/5.*NQ5V*NQ5V*NQ5V*
MM9`A6L?$2['C5HT\,GQ,>(AQXD=*X4>D\VJ\O?"GTR;(7CTP+?"OP)=BKL5=
MBKL5=BKL5?_0]4XJ[%78J[%78JUBKL@"J`U#6-/L5_TB=4_R/V\M`5C]UYZ0
M?[RVW+_+D:@S-AH'#\=!-YWU0_8CB3Z#F3'LX+XZ7>8OS"U[3?+=_J<2V_KV
MWH>GR7]W^^D]/_?F8NHTO"[;V>QC7R`\_P`?S6&:=_SD1K:R(NH:;!-#^UZ#
M/&X_Y&>MF-"+VN7V'-;2^[_JHS_RO^</E#6IDM_5.G7+#^YNJK_R4_NOQR!W
M>:UWLUETFYY?C^DS]71A5&!]\BZ6^B[%6\5=BKL5=BKL5=BK_]'U3BKL5=BK
ML56G(F20IS31P1-)*W%%W+')P!+7DE3"]8\W74LC0V#"*$?[O_;;-C@T=<W&
MEF8V[R,[N[<W?_=F;4>D.+*;LLX0QMV-A:2GSE_R@NM_]&G_`%$QYKM:;#UW
MLA'_``Z'^?\`],Y/&.[?1FH$Z?9^L/\`.79)G`T*++?*'YG>9/++QQ).U[IH
MVDLI2">'_%4G^Z\;>:[4]F,6J)E])/X_GQ?0_E#SAI'F?3EO=.8AD^">!OMQ
MOW#X'RWM#LN>EGO^/M9`J)Q-.AP$EQ)'Q!2KD&3L5=BKL5=BK__2]4XJ[%78
MJ[%5&6:..-G=N*)]LX1"RQMY]Y@UV?4I^,3,EFGV$_GS<:73"G`SS2C,Z$FJ
MET4,\\OI1*SN_P#NM,&0[+X;)+#R3=2?'>R+%_D)\;_?FLGK2Y$<*<1>3='B
M^VK2_P"NV8LM=)R(X`Q#\W]'T[3_`,O=2>UCX.[6Z?:_Y>(\CXYES>F]DHUK
MH?Y__3.3YS'VFR!A;Z[+ZH?YS8%!A93/'R;(KBUQ$XICY=\R:OY?U2+4-.G:
M*:-_WD?[$J?[[DR+@]I=E0U>,WS_`!YOJ7R=YGL?,V@0:K;?"7^">&M3'(/[
MQ#\L#XYKM+^6RF)9%D7%;Q5V*NQ5V*O_T_5.*NQ5V*M8JQ#SQJ+*D-DC#X_C
MG3VS8=G8Z-N/GDQ'-SEY."KV-I-?3K;P+R=_^$S'S2&(,X0>C:3I5MI]LL42
MA6_;?^8YHL^3Q2Y\`F&5MCL50EW86EW`8+F))H>I21>:_<<G:<<O"&S']=LO
M)&B:9+J>I6%I;6D.\DGU=&_4APVY&ERY,IH?>@]#F_+;S-%)^B8+"Z"?WD8@
M177_`)YR1C]6&V[51SZ8>K[WF_YS_E[I>DV\.M:/;?5X'?A?(C4C7_??[O%Z
MWV3[:,Y<,OQ]CR4"@Q?1)"YLV_*'S2^A>:X8Y9.-AJ/^C3AOL"3_`'6^+RWM
M9H#GQ6!O%]0D+096^3@\+>!([UV*NQ5V*O\`_]3U3BKL5=BJE/.D,#S-]B->
M6*O*[V[>[O);AOMS-S&=)BQ"+KLLE++9M<7HOEW1QI]@J.J_6'^*2F<]J=0<
MI=B(4F]`!3,6$:;`NR2NQ586%:'?#2\-C=B'YF^6M1\Q>5KG3=-,?UF5H6C$
MK<$_=2"3K]&3!V=CV7K(8<@)Z,1_*?\`+#7_`"WK4^IZI)$@>#T$AB;G^VA_
MYEX7>>T7;>'4Q`B/O_XE`_GMYLX6:>6X()8VF=7FGECXQ^G&:\(Z_P!YB.3/
MV0T(GDX^YXIB^H1Y6T308HH9-B^J/RSU\ZYY0LKIVYW,,8M[K_C)%L<@^(=N
MZ3P<Q'1EQ:E?;%UTS453(I=BKL5?_]7U3BKL5:[XJ$@\X7'I:0ZKUF;AF1H8
MW)QLS`<W\OJ<613?RI8_6=84NOP0?'F+VA+TMF(/1LT3GMXJ[%78JMV!J<*.
M*@PC\V=:U/2/)]W=:;*8+I6A].9>W[Q,E6UNW[&T4,V41/(L$_*/\QO-VK>9
M1I6JW'UZVFB=_498T=7CI_OL8AZ/VC[`TNGQ<6,<)]\Y?[N3T?\`,+0=.UCR
MM?PWR*6B@DEMY7_W7)&A(?Z,(>5[&U6;%E!@:W$?X7REOXX3D?<.*#M_'*B4
M\4'M/_..FJ!1J^EMUHES%_R;D_YEY:7S7VVQ3&02>V$`_(Y67B/KCNJX$NQ5
MV*O_UO5.*NQ5K$*&*^?6_P!#M5\9<V'9T?4XV9AF;?)S<"V7>1(OANIC]OX$
M.:KM*7)SL`9#^F])^O\`Z-^NP?I#CS^J>K'Z_P#R+K7-:Y2!T3S=Y;UJ.>73
M=0@N$@YI.BR`O%Z,CQR>I'UBWC[XJJ_XI\M?54N_TI:?5I.:QSF>/TV]+^\_
M>5IMBJ6>=?/%IY:\GW'F:&-=1@1H$@2*1`DOUJX2&.DG3_=N*IC_`(F\N_5X
MYVU2T]&?GZ<GKQ\&]+^\X&OQ<>^%>'Q([)+^D/*GFW0;6VU8I%;:LSBVL;B:
M..:4PR?[K]*0F3^[_P!TLV*Z2>3#+;]##/(_F3R-:>;[O3O+FC)'8VKR6=UK
M_P!;B?@\4?UF2L<LAF-J!_N_[/+)6[#6=I:O4Q_>_P#3O_>"*?\`YA:G>:MH
M4]EY;O\`3C;.OIZG?2W4:"*.7_=?MZPQ1V4,$)7D/+RD\CB_*+S)+:?7+>\T
MRXL^7'UX;KU(^?SBCR8@'O?]'.E[C_LO^(6_\JJ\P_\`+58?\CG_`.J>6C"$
M_P"CK2]Q_P!E_P`0S;\HO(VLZ'YGDN[BYM98FMGB=+>3U'!$B?Y`RJW0]M]O
MX];"HCE^/YL'MHZGPRHO&1Y[+\#8[%78J__7]4XJ[%6L0H8KY]7_`$.U;PES
M8=G2]3C9F&9M\G-P*9=Y$:J7:>+(^:KM*/)S\!>=ZK^5&IQ>8YO,M]-I\&D:
M;JMWYBGUJW+IK,L?IR$6CRB.D4,(_<_[T?9CS6N2Q3RS^2'F7S1Y)TO48KJQ
MT-[G0_1M'M#(T]Y^D)([J3](R=?2]+]SZ'^D?WN*LH_Y4->W$VFO/::;#;VU
MQJ5[>:=ZUQ=027=U9QVMM)66*#_=L?KW'[C_`'U_?XJGUW^5VMK^5'E[R9"+
M&]N=*EL9-0M[J22.TN4M)/5EC,GI3R^E-*/]\8JQ[2O^<?M06\>?6DTFXM..
MJWMGI42R"UM]3U'T/2$41C_N(8K;_LVQ5#:%_P`X\ZOIUYI9OYK34K6"UTZ"
M1S<W$,EE)92>K+]5_=_O8IYOWW_'MBJ2^5?RKUCS+Y(;5-$CL]+N=3;S!&[S
M+)`_^Y"Y^JQ?W47]U#:1W'_(W%4+^:GDFU\E:Q;SVL.G6VDZC>V+Z79\XX(%
MCTBSN!+]9^M1_4O6N)KG_=_UC%7I7D:VT2V_)_1OT-97&GV=S\<=O>I&)V<R
M2>I)*(NOK^/_`"S^EF7HH^IJU$MFLWW1UA3[R4G+6&?_`(J?]>:_M$[.9@9\
MN:.#FKLFAV*NQ5__T/5.*NQ5KOBH8_YRMS+H[LHJ86#YD:&52<?,P+-_+ZG$
MD$W\J7WU;6$YM\$R\,Q>T(>ELQ%Z*PY+FB<]RH$3BN*KL5=BKL5=BKL54YH8
MY%XNJO\`ZV*L,\\7G*>"T5OL+SDS::&/5P<TF,9M9N*&7>1+?]U=7'&G-^"?
M+-+KYN9@9=FMQN:NR:'8J[%7_]'U3BKL5=BJA=01S0/"WV)%X8J\MNK=[:YE
MMY?MPOPSI,64%UF2*E]E^:9;+=<;T7R[K":C8*SLOUE/AG3WSG-1ICB+GB:;
M@U%<QH2ML#>35O%78J[%5FQ%3D92X62$U*_@L;5KF4_`G['\V6XH>)LUF;S2
M]NYKNYEGD^V[9T$<-"@ZO)NI9+Z5A%Z7HEC]3TR"(K\?'F_^OG/ZB7$2[=,L
MQX(;R:NQ5V*O_]+U3BKL5=BK6*L2\Y:0TB"_B7[&TX_R/Y\S]+EHTXN:+#\W
M4=PXP5]/U&ZTZY2XMV_XR1_SY3FQC*%A/=Z!HVOV6I1T0\)Q]N!NHS19\/A%
MSX&TVREL;Q5V*M8J@=3U.TT^W]6X;C_(O=LGCQ>(6,RP'6M:FU2?DR\($_NT
MS=:;3>&'`R3W2[,R$MFHLA\I:*]S<F[F6D,#5C_RGS5ZS/6SE88L\S3\5N8W
MAY*[)*[%78J__]/U3BKL5=BK6*K7166A&V&V,PP#S'Y<>RE^L6Z\[-NH_DS;
MZ35@"BX,X)'FQXK86Y'=6YJW!_\`(QX+7Q$^M/..J0+PEXW'^M]O-7+1-D<R
M;0^>K1O[ZVD7_4^/]68TM$7)CG"Z3SUIP^Q!*_R&,=$6OQPEMWYWU&3X+>*.
M+_+^WF1'0KXZ07%S=7,OJSRM*_\`E9L<>`1<3CM2R4XHM,M$T6;4Y_A^"%/[
MQ\PM3J13;C@]"L;2"TMTMXEXHBYII3LN?`(G`R;Q5V*NQ5V*O__4]4XJ[%78
MJ[%5N1!M*UXHY%XN.2GL<F-F!@Q/6_)W(M-IQX?\4?\`5/,[%JCU:)86+2VT
M\#<+B-HG_P!]NN;7%EL.++&I9;QM5.QV6W8[+3L>-::1'E;A$K._^^TR)S4R
MC!DNB^4;J=O5O^44/^^_VVS5:C6=SE1PLRM;.VMH%A@0)&G1!FNG(ERA!6.V
M0C%F`WDD-XJ[%78J[%7_U?5.*NQ5V*NQ5V*M8J[%5&YL[6Z3A<1K*G\CXJD%
MWY)TV7XHGDMS_D_'F3#7R:I8[0$OD*?_`'7=AO\`77,J/:)<:6!T/D*Z_P!V
M7:K_`*BX3VB67@(R#R-8JW.>>28_\!^K,>>ODGP$\LM+L;/_`'E@6+_*&8I+
MEHS*B%;R:NQ5V*NQ5V*NQ5V*O__6]48JDGF#SMY2\N>E^G=7M-+>;^[2[F2+
ME]^*J6I^>_)FE7-O::GKEC9W-WQ^KQ37$:._XXJUJ_GGR?I$_P!5U36K&RN0
MD<Q@N+B.-_3ED]*.2A/>7%4EM/SD\A2>:=2\LSZG'8ZKIL\=L\=XT<"2R2_\
MLY)_>XJGVM>>?)^A745IK.LV6GW5S_<07$Z1N_T$XJLU7SUY-TB=H-4UNRLK
MA8OK/ISW$:/Z%?[RE?[O%4/JWYF?E[I%PMMJ?F+3K2Y<?`DMS&'_`%XJE=C^
M<7D+4/.<OE&UU!)-3AC#B821>A++7^XBD]3]Y-O_`'6-A'$FUO\`F/Y#G:\6
MW\Q:=*U@GJ7G&ZB/I1_SR;[8.,)>6:!^>'FCS#KDU[I3Z"GE>'4H])33KN]]
M#4YC*?W=Q&3^Y_?C_>:'_CX]*;)\09,K\G?F?+?ZIYVDU^>ST[0/+.I?HRTO
M'/H?W5?5,LDLG_&/&PK/=$US1]:L5OM'OH-1LW^Q/;R)(GWQY6"Q2^^\\^3[
M'6(-$O-9LK?5KED2WL'FC^L,\II'^[Z[Y,!5S>>O)ZZU^@6UNR_3'_+#Z\?K
M_P#(O`JE?_F)Y%TVZDM-0U^PM;J&1(9()KB-'227HA!.*HO2O-OEG5K^[T_3
M-4M+V\LMKR"WF21XNWQ@'%7>8/-OEGR]`MQKNJ6NF02']W)=S1Q<O]2IWQ51
MLO.GE+4/T=]3UFSN'U;U/T8J3QGZQZ/][Z7^_/1Q5&Z5KNCZO%++I=W#>Q02
MO;3R0.)`DT7]Y'MW&*IGBK__U_5#8J^?_,/E/5M/_-W7=?UGR3)YXTW6HH$T
M><?5WCL_2C].2.2.7^Z_XS8JD/G'\NO-J:UY\L$\G_I^Y\URI^@/,'*W]"R@
MK_=R>K_=>A_S+Q5D.@?E%=W?YB72^:-.6\TS2?+6FZ1IFI7$:2(]W%$GJ7,7
MJ5_>P?O,5>:^7/+NM^=='\VZ/H?EQ[R#7_,#R6_FN^D22.SMX9/M^I)^_FF_
MZJXJS3S/Y(\TZ?J_FZQD\I-YQNO,EO!;:'Y@<Q\+1/J_H^G+ZO\`<^A3UL51
MOD/\E)W\]M#YVTJ/5M)T70+33+.[N%YP2W'][+Z7_&#U)8,58=>_EMYPGT>Z
M\OS^2KB?6KWS#ZVI^:_W#I):?6#_`'=?WWH^EOBK*;[R'YO3\Q/S`MX/+:^A
MYHLI(-$U^/TX[>S_`-"DCIX^K/+Z4.*I-Y)\E:AH:0:UK^A:S9IY1TB^DE&H
M?4/T9S^KR>K%%%%'Z\T4\I];%6O(OD+6+CR-^5,]EI;31G6GUS7+N)8_@CAE
M?ZMZG_/+%5*+\K/S%_P58:K=65Z+QO,5WK.MZ/9_5_KW[WTXHI8O5]>&7T/3
MD_<?\78J]$_*S2?,7E)8H[/R_JC0^9M3GGU>34[BS2>RI&/])]*UC]']_P#[
MY_XJQ5)/R[\HZ]Y;\UZE9>9/)K:SK%_JKWEOYY?T+A$C_P!U2_O?WT7HXJQ+
M3_RF\[SZ79^2Y?*OU?6X=<&IW_GIVC]-X/4J9(I?[[U?^*,53WSA^6^O7WD_
M\QKZ+R[)>>9O,.N^AI[/'&9UTR&2/TY(_P#?47[N3%4=%Y6\V^4OS,U;S!Y>
M\I->Z?HVA6FDZ7:V[1VJ7LGJ6_JR>H:_W/[S_D5BJG^8OE+S=<?F5J^O7'E"
M7S/:W^AI:Z!Q,#QV%WZ?[P2>K_Q;ZG_(S%4'HGD[S[Y8O?RSU2V\LW&K+H>D
M7<$]I%)'`\%Y>>IZGJ&7^[_O<5>C_P#.//EO6]#_`"]]+7+1['5;S4+N]N+6
M7[:>M)W_`.1>*O4,5?_0]48J[CBKL54W1'5D_G7%4B\D^2=!\FZ"FB:'')%8
M([S<)9#(_.7K\>*LAQ5V*NQ5V*I=K6B:=K>E7>DZC%ZVGWT3P7<)9TY)+L>F
M*K](T?3M)TFUTJP@$%C8Q1P6L"[\8XMD_5BJ.Q5V*NQ5W'%78J[%7<<5=QQ5
MV*MXJ__1]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
$8J__V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
